

Review Article

The Intestinal Redox System and Its Significance in Chemotherapy-Induced Intestinal Mucositis

Qing-Qing Yu ^{1,2}, Heng Zhang ³, Yujin Guo ², Baoqin Han ^{1,4} and Pei Jiang ²

¹Laboratory of Biochemistry and Biomedical Materials, College of Marine Life Sciences, Ocean University of China, Qingdao 266003, China

²Jining First People's Hospital, Jining Medical College, Jining 272000, China

³Department of Laboratory, Shandong Daizhuang Hospital, Jining 272051, China

⁴Laboratory for Marine Drugs and Bioproducts of Qingdao National Laboratory for Marine Science and Technology, Qingdao 266235, China

Correspondence should be addressed to Baoqin Han; baqinh@ouc.edu.cn and Pei Jiang; jiangpeicsu@sina.com

Received 2 March 2022; Revised 4 April 2022; Accepted 9 April 2022; Published 9 May 2022

Academic Editor: Jing Zhou

Copyright © 2022 Qing-Qing Yu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Chemotherapy-induced intestinal mucositis (CIM) is a significant dose-limiting adverse reaction brought on by the cancer treatment. Multiple studies reported that reactive oxygen species (ROS) is rapidly produced during the initial stages of chemotherapy, when the drugs elicit direct damage to intestinal mucosal cells, which, in turn, results in necrosis, mitochondrial dysfunction, and ROS production. However, the mechanism behind the intestinal redox system-based induction of intestinal mucosal injury and necrosis of CIM is still undetermined. In this article, we summarized relevant information regarding the intestinal redox system, including the composition and regulation of redox enzymes, ROS generation, and its regulation in the intestine. We innovatively proposed the intestinal redox “Tai Chi” theory and revealed its significance in the pathogenesis of CIM. We also conducted an extensive review of the English language-based literatures involving oxidative stress (OS) and its involvement in the pathological mechanisms of CIM. From the date of inception till July 31, 2021, 51 related articles were selected. Based on our analysis of these articles, only five chemotherapeutic drugs, namely, MTX, 5-FU, cisplatin, CPT-11, and oxaliplatin were shown to trigger the ROS-based pathological mechanisms of CIM. We also discussed the redox system-mediated modulation of CIM pathogenesis via elaboration of the relationship between chemotherapeutic drugs and the redox system. It is our belief that this overview of the intestinal redox system and its role in CIM pathogenesis will greatly enhance research direction and improve CIM management in the future.

1. Introduction

Chemotherapy-induced intestinal mucositis (CIM) is defined as an intestinal disorder caused by chemotherapy in ESMO (European Society for Medical Oncology) [1, 2]. Based on the differences in chemotherapeutic drugs, the clinical incidence of CIM can be up to 40-76% [3]. However, the recommended drugs in ESMO, such as ranitidine, octreotide, and omeprazole, exhibit poor efficacy [2], which suggests the need for clarification of the underlying mechanism behind CIM pathogenesis.

The following describes a typical CIM presentation in a five-phase model: (1) initiation, (2) upregulation and mes-

sage generation, (3) signaling and amplification, (4) ulceration, and (5) healing [4–6]. Existing studies revealed that ROS is rapidly produced in the initial stage, at the time when chemotherapeutic drugs cause direct damage to the intestinal mucosa cells and produce mitochondrial dysfunction. Although the intestinal mucosa is normal at this stage, the cascade reaction that eventually results in submucosal damage has already initiated [7]. However, the mechanism involving intestinal oxidation-reduction (redox) system, ROS production, and induction of intestinal mucosal injury within CIM is not fully understood.

This review has two segments, the first segment details intestinal physiological redox pathways, and the second

summarizes available information on CIM. To reiterate, our first segment discusses the intestinal redox system, including the composition and regulation of redox enzymes, as well as reactive oxygen species (ROS) generation and its intestinal regulation. This section details the redox system-mediated modulation of the physiological intestinal function. The second segment discusses the redox system-mediated modulation of CIM pathogenesis via elaboration of the relationship between chemotherapeutic drugs and the redox system and the involvement of ROS in CIM development. We also discussed the significance of intestinal redox system in CIM.

2. Overview of Oxidation-Reduction (Redox) System in the Intestine

The digestive system is responsible for digesting and absorbing nutrients and possesses unique gut morphology. The interaction between intestinal flora and intestinal redox system is not discussed in this review. Since the intestine links an organism with its outside environment, it automatically facilitates protection against luminal toxic agents, which is also primarily done by the redox system. Thus, it is necessary to elucidate the composition and regulation of the intestinal redox system to explain the physical mechanism of the digestive system, particularly in terms of absorption and defense function.

3. Enzyme Related to OS Generation in the Intestine

3.1. Nicotinamide Adenine Dinucleotide Phosphate (NADPH) Oxidase (NOX). NOX belongs to the membranal flavoprotein NADPH-dependent oxidoreductase family, and it accelerates oxygen (O_2) reduction to form superoxide ($O_2^{\bullet-}$) (Table 1). Thus far, six cytochrome homologs have been identified within the subunit of the phagocyte NOX, namely, NOX1, NOX3, NOX4, NOX5, DUOX1, and DUOX2. Among them, NOX1 is ubiquitously present in the colon (Figure 1) [8–10]. However, the expression is scarce in the proximal colon and relatively high in the distal colon [11, 12]. Using in situ hybridization, it was shown that NOX1, within the colon wall, was evenly distributed between the apical surface and crypts [12] or exhibited concentrated expression in the lower regions of the crypts [13]. Moreover, the largest expression is evident on the mucosal surface. DUOX2 is also present in the distal gastrointestinal (GI) tract; specifically, it can be found in the cecum, sigmoidal colon, and rectal glands [14–16].

In terms of structure, NOX has six N-terminal transmembranal α -helices, a flavin adenine dinucleotide- (FAD-) docking pocket, and a C-terminal NADPH-docking pocket. Multiple reports indicated that the NOX1 molecular mass ranges between 55 and 60 kDa [17–19]. The human NOX1 gene 5'-region is known to possess elements that specialize in interaction with signal transducers and activators of transcription (STATs), interferon regulatory factor (IRF), AP-1, NF- κ B, CREB, CBP/p300 elements [20], and GATA factors [21]. NOX1 overexpression in intestinal epi-

thelial cells is strongly associated with GATA-interacting sites [21], whereas interferon- γ overexpression is modulated by the interaction between stimulated STAT1 dimers and γ -activated sequence (GAS) element [20]. DUOX enzymes typically undergo glycosylation. DUOX1 and DUOX2 exist in one of two N-glycosylation states. One is an elevated mannose glycosylation, which is typically observed in the endoplasmic reticulum (ER), and presents as an 180 kDa protein band on gel electrophoresis. The second is a complete glycosylation status, which is typically identified on the plasma membrane, and is represented by a 190 kDa protein band on gel electrophoresis [22, 23]. Based on carbohydrate content analysis of membranal DUOX, the presence of particular oligosaccharides involved in Golgi apparatus (GA) processing was identified [24]. DUOX2 is typically located all over the GI tract, namely, the duodenum, colon, and cecum [14, 16], and its transcription is triggered by interferon- γ in response to the spontaneous differentiation of postconfluent Caco-2 cells [14].

NOX is activated after the assembly of additional proteins, such as membranal $p22^{\text{phox}}$, which stabilizes NOX proteins and interacts with cytosolic agents and proteins $p47^{\text{phox}}$, $p67^{\text{phox}}$, small GTPase Rac, and $p40^{\text{phox}}$ (Figure 2). Synergistically, these proteins activate NOX. Once stimulated, $p47^{\text{phox}}$, along with the bound $p47^{\text{phox}}$, relocates to the membrane. $p47^{\text{phox}}$, in this scenario, is thought to behave as an organizer. Upon translocation, $p67^{\text{phox}}$ directly binds and activates NOX2. Thus, $p67^{\text{phox}}$ behaves as an activator [25]. Simultaneous to this process, GTP-binding protein Rac also translocates to the cell membrane, whereby it activates NOX2 [26]. Lastly, the newly discovered subunit $p40^{\text{phox}}$ [27] is thought to play a nonessential, but regulatory role. The newly discovered subunits were termed as NOXO1 (NOX organizer = $p47^{\text{phox}}$ homolog) and NOXA1 (NOX activator = $p67^{\text{phox}}$ homolog). Interestingly, even though the expression systems employing mouse proteins demonstrated potent constant activity of the NOX1/NOXO1/NOXA1 network, using human proteins resulted in only diminutive activity. NOX1 activation, in such cases, was only possible via introduction of PKC activator phorbol 12-myristate 13-acetate (PMA) [25, 28]. Emerging evidences also suggest that small GTPase Rac modulates NOX1 activity [25, 29–32]. Rac interacts with the TPR domain of the activator NOXA1 [25, 29, 30], but, similar to NOX2, the Rac-mediated NOX1 stimulation may require two steps and physical interaction with NOX1.

3.2. Xanthine Oxidoreductase (XOR). XOR commonly represents two interconvertible states of the same enzyme: dehydrogenase (XDH) and oxidase (XO) [33]. XOR oxidizes hypoxanthine and xanthine to form xanthine and uric acid, respectively, as part of the purine degradation process. In humans, XOR is primarily located in the liver and intestine [34], whereas other human organs display minute XOR activity (Figure 1) [35, 36]. Within cells, XOR is primarily found in the cytoplasm and sometimes in organelle membranes like peroxisomes (Table 2)

Upon transcription and translation, XOR forms XDH, a ~300 kDa homodimer that consists of four redox regions per

TABLE 1: Major oxidoreductive enzymatic reactions of oxidoreductases in intestine.

Enzyme name	Enzymatic reaction	Cofactor
NADPH oxidase	$\text{NADPH} + 2 \text{O}_2 = 2 \text{O}_2^- + \text{NADP}^+ + \text{H}^+$	
Xanthine dehydrogenase	$\text{H}_2\text{O} + \text{xanthine} + \text{O}_2 = \text{H}_2\text{O}_2 + \text{urate}$	[2Fe-2S] cluster, FAD, Mo-molybdopterin
Nitric oxide synthase	$\text{H}^+ + 4 \text{O}_2 + 3 \text{NADPH} + 2 \text{L-arginine} = 4 \text{H}_2\text{O} + \text{L-citrulline} + 3 \text{NADP}^+ + 2\text{NO}$	Heme, FAD, FMN, tetrahydrobiopterin (BH4)
Myeloperoxidase	$\text{Chloride} + \text{H}^+ + \text{H}_2\text{O}_2 = \text{H}_2\text{O} + \text{hypochlorous acid}$	Ca^{2+} , Heme <i>b</i>
Catalase	$2\text{H}_2\text{O}_2 = 2\text{H}_2\text{O} + \text{O}_2$	Heme, NADP^+
Superoxide dismutase		
SOD1		Zn^{2+} , Cu^+
SOD2	$2\text{H}^+ + 2 \text{O}_2^- = \text{H}_2\text{O}_2 + \text{O}_2$	Mn^{2+}
SOD3		Zn^{2+} , Cu^+
Glutathione peroxidase		
GPX1~3, 5~8	$2 \text{glutathione} + \text{H}_2\text{O}_2 = \text{glutathione-2S} + 2 \text{H}_2\text{O}$	
GPX4	$1 \text{ hydroperoxy polyunsaturated fatty acid} + 2 \text{ glutathione} = 1 \text{ hydroxy polyunsaturated fatty acid} + \text{glutathione-2S} + \text{H}_2\text{O}$	
Peroxiredoxin		
PRDX-1~5	$[\text{thioredoxin}]\text{-dithiol} + 1 \text{ hydroperoxide} = [\text{Thioredoxin}]\text{-2S} + 1 \text{ alcohol} + \text{H}_2\text{O}$	
PRDX-6	$1 \text{ hydroperoxide} + 2 \text{ glutathione} = 1 \text{ alcohol} + \text{glutathione-2S} + \text{H}_2\text{O}$	
Heme oxygenase		
HO-1	$\text{Heme } b + 3 \text{O}_2 + 3 \text{ reduced } [\text{NADPH-hemoprotein reductase}] = \text{Biliverdin IX}\alpha + \text{CO}$	
HO-2	$+ \text{Fe}^{2+} + \text{H}^+ + 3 \text{H}_2\text{O} + 3 \text{ oxidized } [\text{NADPH-hemoprotein reductase}]$	

subunit: one molybdenum cofactor (Mo-co), one flavin adenine dinucleotide (FAD) location, and two Fe_2S_2 locations (Table 1) [37]. It is a critical enzyme in the last step of endogenous and exogenous purine metabolism. XOR typically exists in two interconvertible forms: XO promotes O_2 reduction in one electron transfer. In contrast, although XDH reduces O_2 , it prefers nicotinamide adenine dinucleotide (NAD^+) reduction via two electron transfers [35, 38]. Both forms also oxidize hypoxanthine and xanthine to UA via binding with Mo at the docking site, where it donates two electrons, thereby reducing it from Mo^{6+} to Mo^{4+} . Mo^{6+} is then formed again via transfer of two electrons from Mo^{4+} to flavin adenine dinucleotide (FAD) using an iron sulfur center. This generates flavin adenine dinucleotide hydroquinone (FADH_2), which, in turn, donates electrons to either O_2 forming $\text{O}_2^{\bullet-}$ anions and hydrogen peroxide (H_2O_2) or to NAD^+ , thus generating nicotinamide adenine dinucleotide hydride (NADH). Given these evidences, the XO-mediated catabolic reactions occur in conjunction with ROS generation [39].

Despite extensive studies on XOR biochemistry, little is reported on the different types of XOR modulation (Figure 2). The human XDH gene resides on the p22 band of chromosome 2, and its protein comprises of multiple potential docking sites for translational modification, namely, four CCAAT/enhancer docking sites, three IL-6 responsive elements (RE), and a NF- κ B site, as well as TNF- α , interferon- γ , and interleukin-1 REs [38, 40]. In addition, although multiple studies reported severe hypoxia-

mediated modulation of both transcriptional and posttranslational XOR [41–43], moderate hypoxia (10% O_2) also induces marked upregulation of XOR levels, activity, release from endothelial cells, and XO-based ROS generation [44].

3.3. Nitric Oxide Synthase (NOS). NOS is a collection of enzymes that promote nitric oxide (NO) synthesis from the nitrogen residue of L-arginine, under regulation of NADPH and molecular O_2 . The NOS directly interacts with FAD, flavin mononucleotide (FMN), heme, tetrahydrobiopterin (BH4), and calmodulin (Table 1). Till now, three NOS versions were identified in mammals. Among them, nNOS (i.e., type I, NOS-I, and NOS1) was the first discovered isoform, and it predominately resides within neurons. The next isoform is iNOS (i.e., type II, NOS-II, and NOS2), and it can be induced in many cells and tissues. The last isoform is eNOS (i.e., type III, NOS-III, and NOS3), and it was initially recorded in vascular endothelial cells. In addition to this, nNOS and eNOS were also identified in the intestinal myenteric neurons and enteric arterioles [45, 46]. It was reported that the iNOS isoform is activated by inflammatory cytokines employing the NF- κ B pathway. Moreover, in 2012, while examining NF- κ B signaling in colitis, Gochman et al. reported relatively high iNOS expression in human colitis tissue [47] (Figure 1).

Structurally, the three reported isoforms are comparable to one another. All are made of dimmers of two similar subunits [48, 49]. In addition, each monomer consists of three domains, namely, reductase, oxygenase, and calmodulin-




FIGURE 1: The anatomical, cellular, and subcellular locations of the intestinal oxidoreductases. The anatomical location of oxidoreductase is shown in red color (the top line). The cellular and subcellular locations of oxidoreductases are represented by yellow or brown color.

binding domains. The reductase domain harbors docking sites for FMN, FAD, and NADPH. In contrast, the oxygenase portion interacts with tetrahydrobiopterin (BH4). The primary function of the reductase portion, which comprises the functional groups FMN and FAD, is to donate electrons from NADPH to the oxygenase of the corresponding subunit. Subsequently, the calmodulin-binding domain regulates all NOS isoform activities [50]. All NOS isoforms

promote the same reaction. At the initial step, NOS catalyzes L-arginine oxidation to form an intermediate molecule, N-hydroxy-L-arginine. This is next oxidized to L-citrulline to generate NO [51].

NO, an end-result of an NOS-based reaction, modulates both NOS expression and activity (Figure 2). Its modulation of amino acid residues to form an S-nitroso group reversibly suppresses NOS activity [52]. Scientists demonstrated a




FIGURE 2: Intestinal redox regulation. OS regulation via oxidoreductases maintains normal physiological intestinal homeostasis, similar to the balance of the “Tai Chi” theory. The regulation of NOX, CAT, PRDX, and NOS was mainly at the posttranslational level; the others were at the translational level.

negative NO feedback loop using S-nitrosylation [53]. In this process, both NOS1 and NOS2 undergo S-nitrosylation. However, the dynamic modulation of their physiological function using this process needs further investigation. Moreover, phosphorylation of nNOS and eNOS isoforms modulates NOS action. Fluid shear stress phosphorylates eNOS, thus enhancing noncalcium-related NOS action [54, 55]. Multiple reports revealed that protein kinase Akt-mediated phosphorylation of the Ser¹¹⁷⁹ residue of eNOS [56, 57] augments electron flux via the reductase domain, thereby increasing NO production [58]. Alternately, CaM-dependent kinase-mediated Ser⁸⁴⁷ phosphorylation of nNOS drastically reduces NOS activity [59, 60].

3.4. Myeloperoxidase (MPO). MPO is a component of polymorphonuclear leukocytes that protects hosts from foreign pathogens. In fact, it possesses proven microbicidal activity against a myriad of organisms. In activated PMN, MPO promotes hypochlorous acid production. Under physiologic conditions, it triggers hypochlorous acid synthesis, as well as other toxic intermediates that greatly augment PMN microbicidal activity. Under regulation of H₂O₂ and a halide, such as chloride, bromide, or thiocyanate, MPO triggers reactive O₂ intermediate production, which includes hypochlorous (HOCl), hypobromous, and hypothiocyanous acids, respectively (Table 1) [61, 62]. In activated neutrophils in the peripheral blood and tissues (Figure 1), MPO is secreted into phagolysosomes and the extracellular space (Table 2). Moreover, MPO mediates regional tissue damage and triggers inflammation in a myriad of intestinal inflammatory conditions [63–66].

Recent reports examined the biosynthesis and structure of MPO [67–69]. In brief, MPO originates from a singular gene in chromosome 17. Once translated, it forms an 80 kDa protein, which undergoes cleavage to generate a signal peptide. The N-linked glycosylation of the signal peptide, along with subsequent deglycosylation produces a 90 kDa

enzymatically inactive apoproMPO. However, with heme introduction, apoproMPO is altered to the enzymatically active proMPO, which briefly interacts with calnexin. The proteolytic cleavage of proMPO removes the N-terminal 125 amino acid proregion, and a 72–75 kDa protein remains. A second proteolytic cleavage produces the heavy 59 kDa α -subunit and light 13.5 kDa β -subunit of MPO. This, in turn, forms a heavy-light protomer. A mature MPO possesses a molecular mass of 150 kDa and has a pair of heavy-light protomers, whereby the heavy subunits are connected via a disulfide bond.

The MPO gene sits on chromosome 17q22 and possesses twelve exons [70]. MPO is primarily expressed during the advanced myeloblast to the promyelocyte phases of normal myeloid formation [71, 72], and MPO expression is silenced once cells begin to differentiate [73]. The MPO gene expression is promoted by the excessive demethylation of the 5' flanking region, which essentially opens up the chromatin structure for transcription to ensue [74, 75]. Upon transcription into mRNA, alternative splicing cleaves the original mRNA to produce secondary mRNA measuring 3.6 and 2.9 kB [76]. The MPO gene expression is also modulated by the transcription factor (TF) AML1, and, therefore, AML1 site integrity is crucial to the transcription of the gene (Figure 2) [77, 78]. The Reynolds' study recognized an allelic polymorphism, -463G/A, in the promoter region of the MPO gene [79]. It harbors an Alu receptor response element (AluRRE), which can interact with multiple nuclear receptors, including Sp1 [79, 80]. In presence of an intact -463G Sp1 site, the MPO transcription rate increases by 25-fold, compared to the -463A Sp1 location.

4. Antioxidative Generation-Related Enzyme in the Intestine

4.1. Catalase (CAT). The oxidoreductase CAT accelerates the splitting of H₂O₂ to water and O₂. There are three categories of CATs: normal CATs or monofunctional (for example, mammal type CATs), bifunctional CAT (such as, peroxidases), and pseudo CAT. The human CAT has a standard monofunctional heme-harboring CAT, with a prosthetic ferric protoporphyrin IX group that interacts with H₂O₂. It is primarily found in peroxisomes, with a molecular mass of about 220–240 kDa [81]. In mammalian tissues, liver and erythrocytes exhibit the largest CAT activity, kidney and adipose tissue show relatively elevated activity, lung and pancreas display intermediate activity, and heart and brain show very little activity (Figure 1). Moreover, CAT forms particles within the small intestinal epithelium [82].

The human CAT is a tetrameric protein, and each of its subunits is further categorized into four domains, namely, the N-terminal threading arm, C-terminal helices, wrapping loop, and β barrel [81, 83]. Each subunit contains a hydrophobic core that has eight stranded β barrels encircled by α -helices. Each subunit polypeptide chain contains residues 4–502. In addition, subunit B also has residue Glu503. The N-terminal threading arm (residues 5–70) forms a bridge between two subunits by forming a long encircled loop

TABLE 2: Subcellular location of oxidoreductases in intestine.

Enzymes name	Cytoplasm	Melanosome	Endosome	Endoplasmic reticulum	Mitochondrion	Peroxisome	Lysosome	Extracellular	Plasma membrane	Nucleus	Golgi	Cytoskeleton	Cell junction
NADPH oxidase													
NOX1									✓				
NOX2									✓				
NOX3													
NOX4				✓					✓				✓
DUOX1									✓				
DUOX2									✓				✓
Xanthine dehydrogenase	✓					✓							
Nitric oxide synthase													
NOS1									✓				
NOS2													
NOS3	✓								✓		✓		
Myeloperoxidase													
Catalase						✓							
Superoxide dismutase													
SOD1	✓				✓					✓			
SOD2					✓								
SOD3													
Glutathione peroxidase													
GPX1	✓												
GPX2	✓												
GPX3													
GPX4	✓												
GPX5~7													
GPX8									✓				

(residues 380–438) surrounding the other subunit. Lastly, a helical domain associated with the β barrel possesses four c-terminal helices ($\alpha 16$, $\alpha 17$, $\alpha 18$, and $\alpha 19$) and four helices made from residues between $\beta 4$ and $\beta 5$ ($\alpha 4$, $\alpha 5$, $\alpha 6$, and $\alpha 7$).

CAT is typically modulated via transcription and post-transcriptional factors (Figure 2). The mammalian CAT promoter is heavily conserved. Therefore, it enables an effective interaction with TFs NF- κ B, Sp1, and WT1/Egr in the core domain. It is also reported that the Fox family members, modulated by the Akt/PKB axis, also contain highly conserved docking sites in vertebrate CAT promoters [84]. Post-translational modifications like phosphorylation (Ser¹⁶⁷) [85], glycation [86], and acetylation [87] reduce CAT activity. Alternately, CAT covalently interacts with p53 [88], and ATM (ataxia telangiectasia mutated) [89] proteins promote CAT enzymatic activity. Furthermore, CAT modulation also includes structural alterations. H₂O₂, along with many other chemicals, abrogates CAT activity [90–92]. The active CAT domain is not directly modulated by H₂O₂ oxidation. Instead, it induces conformational alterations (a catalysis requirement) via amino acid residue oxidation. Exogenous nitric oxide is also known to inhibit CAT activity; however, in this case, the effect is reversible [93].

4.2. Superoxide Dismutase (SOD). SOD triggers the conversion of O₂^{•-} and hydrogen into molecular O₂ and H₂O₂, thereby protecting the cell from toxic O₂^{•-} concentrations. There are three mammalian SOD isoforms, namely, SOD1, SOD2, and SOD3 [94]. SOD1 and SOD2 are ubiquitously found in all cells. Elevated SOD3 levels were detected in select tissues, including blood vessels, lung, kidney, and heart [95]. The Cu/Zn SOD SOD1 is primarily cytoplasmic. However, it can be found in the nucleus, lysosome, peroxisome, and mitochondrial intermembranal space as well [96]. The MnSOD2 resides in the mitochondrial matrix [97]. Lastly, the Cu/Zn SOD SOD3 is typically released into the extracellular space (Table 2) [98].

MnSOD is present both as a tetramer and dimer, and all information related to its structures (reduced, oxidized, and specifically mutated enzymes) is available in the Protein Database. Eukaryotic MnSODs (for example, humans) are typically tetrameric. The monomeric structure has two domains, an N-terminal (primarily) α -helical region and a C-terminal region with a small β sheet and α -helices [99–101]. The difference between the two types of MnSODs is that, in tetrameric MnSODs, the N-terminal region consists of long α -helices that form a hairpin structure [102]. MnSODs possess varied cellular activities at both elevated and reduced O₂^{•-} concentrations. This is known as “gating,” and is typically assessed via a range of stopped-flow and pulse radiolysis investigations [103, 104]. Interestingly, at high concentrations, O₂^{•-} undergoes a biphasic process, whereby there is a rapid loss of O₂^{•-} (burst phase), followed by a reduced loss rate (zero-order phase). Moreover, during proton delivery, there is a reversible isomerization, whereby the bound peroxy moiety is isomerized [104]. It was suggested that residues, such as Tyr³⁴ [105], His³⁰ [106], Glu¹⁴³ [107], and Phe⁶⁶ [108], modulate this process.

The eukaryotic SOD1 is a 32 kDa homodimer, whereby all subunits carry one copper- and one zinc-interacting region close to one another, and it has a disulfide bond between Cys⁵⁷ and Cys¹⁴⁶. Moreover, the subunits fold to form eight-stranded, Greek-key β barrels, having 7 tethering loops, among which, loops IV (residues 49–83) and VII (residues 121–142), also known as the zinc and electrostatic loops, respectively, hold significant function. The zinc loop harbors all four Zn-interacting residues and a disulfide cysteine, Cys⁵⁷. The electrostatic loop harbors a majority of the second-sphere active location residues, namely, the functionally significant Arg¹⁴³, and serves as a gatekeeper that limits solvent access to the metal-interacting locations. SOD1 is generally activated by some posttranslational modifications like N-terminal acetylation, copper and zinc ion introduction, intramolecular disulfide bond generation between Cys⁵⁷ and Cys¹⁴⁶ [109], and dimerization (Figure 2).

4.3. Glutathione Peroxidase (GPX). GPX belongs to a phylogenetically linked enzyme family that employs the reductant glutathione (GSH), which reduces H₂O₂ or organic hydroperoxide to water and alcohols, respectively (Table 1) [110]. The GPX catalytic center is a triad harboring Sec or Cys, Gln, Trp, and Asn [111]. However, in mammalian GPX8, the Gln is substituted by a Ser [112]. GPX1 was the first discovered selenoprotein [113], followed by GPX2~4 and GPX6, which were purified with a selenocysteine (Sec) in the catalytic center [114–118], and lastly, GPX5 and GPX7~8 with cysteine (Cys) [119–121].

GPXs serve an antioxidant role at various locations and cellular compartments. They are widely expressed within the cytosol, mitochondria, and colon (Figure 1) [122, 123], whereby they detoxify H₂O₂ and other soluble hydroperoxides [124–127]. Using this process, they protect erythrocytic hemoglobin from oxidative breakdown [128]. GPX2 is primarily found in the intestinal epithelium, and it is termed as GI-GPX or GPX-GI. In the intestine, it prevents the absorption of food-based hydroperoxides [129–131]. GPX3 is an extracellular enzyme produced by the proximal renal convoluted tubule [118], and it is basolaterally released into the plasma [132]. Several reports also identified GPX3 in other tissues like the basement membranes of intestinal epithelial cells [133]. GPX4, mainly located in the mitochondrial capsule of mature spermatozoa [134], facilitates reactions with more complex lipid hydroperoxides (LOOH) like phospholipid, cholesterol, and cholesterol ester hydroperoxides, regardless of their location status [135]. GPX5 is an epididymal CysGPX in mice, rats, pigs, monkey, and humans, and it closely resembles GPX3. The GPX6 protein is yet to be purified, so its kinetic dynamics is underdetermined. Thus, not much is known about it thus far. GPX7 is a CysGPX that strongly prefers the ER-related protein disulfide isomerase (PDI) as a reducing substrate [136]. This protein is either unexpressed or marginally expressed in breast cancer cell lines [121]. GPX8 is a CysGPX as well, and, like GPX7, it resides in the ER, where it partakes in oxidative protein folding [137, 138].

Based on the above evidences, the most significant GPXs are GPX1, GPX2, and GPX3. The GPX2 transcript is

commonly expressed in all GI epithelial cells [130, 139]. However, the largest concentration is found in the ileum and cecum, which exhibits 2~3-fold elevation in GI-GPX transcript expression, compared to the remaining areas of rat GI [129]. GPX2 is uniformly available in the middle and lower portions of the GI [130]. The largest GPX2 protein concentrations occur in the colonic crypt bases, and it reduces gradually at the top of the crypts or villi [140]. GPX1, which is usually only marginally seen at crypt bases, was remarkably upregulated in the very same areas that express GPX2 [141]. Kidney GPX3 can transport and bind to the intestinal basement membrane. GPX3 interaction is particular and targeted toward certain cells. This indicates that cells regulate their basement membranes to expose GPX3 interacting locations, based on the need of GPX3 enzymatic activity [133, 142].

GPX activity modulation, particularly selenoproteins, depends on the availability of selenium (Figure 2). Scientists studying this process formed the selenoprotein stratification, suggesting that selenoproteins are not generally available with selenium, and in multiple cases, selenium is rate-limiting. Certain selenoproteins degrade fast, whereas others remain till severe deficiency occurs. As a result, selenoproteins that degrade quickly fall low in the stratification, and those with superior stability rank high. Among the various members of SecGPXs, GPX2 leads the hierarchy and then GPX4, GPX3, and GPX1 [143]. To elucidate GPX expression modulation, one must recall the eukaryotic mechanism of selenoprotein biosynthesis [144]. Selenoprotein biosynthesis requires a special tRNA, termed as tRNA^{(Ser)Sec} [145] and a stem loop structure in the 3' UTR, called Sec insertion sequence (SECIS) [146]. SECIS binding protein-2 (SBP2) interacts with a 3' UTR SECIS element to recruit eEFsec, a Sec-specific elongation factor, and SECp43, a tRNA methylase, prior to delivering the entire complex to the ribosome [147]. The eukaryotic initiation factor 4a3 (eIF4a3) binds multiple selenoprotein transcripts to prevent SBP2 interaction and, subsequent, translation [148]. EIF4a3 is activated during selenium deficiency and directly interacts with SECIS elements [149].

4.4. Peroxiredoxin (PRDX). PRDX is a member of a widely expressed peroxidase family that reduces a wide range of peroxides, such as H₂O₂, lipid peroxide, and peroxynitrite (Table 1). They are detected in numerous organisms like bacteria, plants, and mammals. PRDX enzymatic activity requires a thiol-containing intermediate thioredoxin to serve as a reducing cofactor. Based on various locations and functions within cells, the stratification system separates PRDX protein into PRDX1, PRDX2, PRDX3, PRDX4, PRDX5, and PRDX6, and all six categories express in the intestine as antioxidative enzymes [150–155]. PRDX triggers H₂O₂ and organic hydroperoxide reduction into water and alcohols, respectively. PRDX protects cells from OS via detoxification of peroxides, and it serves as a sensor of H₂O₂-based signaling [156–159]. PRDX1~2 participates in growth factors and TNF- α networks via modulation of intracellular H₂O₂ levels [160]. PRDX-4 modulates H₂O₂-mediated upregulation of cytosolic NF- κ B via regulation of I- κ B α phosphorylation [158].

The peroxide active site structure and sequence are highly conserved among all PRDX classes. It contains a conserved cysteine residue, designated as “peroxidatic,” Cys (C_P) that serves as the location of peroxide oxidation [161]. Peroxides promote C_P-SH oxidation to cysteine sulfonic acid (C_P-SOH), which, in turn, interacts with a different cysteine residue, named “resolving” Cys (C_R), to generate a disulfide, which undergoes subsequent reduction via an electron donor to end one catalytic cycle [162]. In terms of C_R, PRDXs are stratified into typical 2-Cys, atypical 2-Cys, and 1-Cys PRDX subfamilies. PRDX1~4 is a member of the typical 2-Cys, PRDX5 aligns with atypical 2-Cys, and PRDX6 is with 1-Cys PRDX [163].

The overoxidation of PRDX1~2 and phosphorylation of PRDX 1~4 are known to decrease peroxiredoxin activity, which, in turn, regulates enzyme activity (Figure 2). The conserved Cys of PRDX1 and PRDX2 is H₂O₂-sensitive and corresponds to Cys⁵¹. The conserved Cys⁵¹-SH undergoes selective oxidization by H₂O₂ to form Cys-SOH, which, in turn, interacts with the Cys¹⁷²-SH of another subunit to generate an intermolecular disulfide. However, the sulfur atoms belonging to Cys⁵¹ and Cys¹⁷² are located relatively far from one another (~13 Å), and, therefore, intermolecular disulfide formation between these residues takes considerable time. As a result, the Cys⁵¹-SOH intermediate is sometimes oxidized to Cys-SO₂H, prior to formation of a disulfide (8, 12–14). Since sulfinic acid does not undergo reduction, Cys-SO₂H-based overoxidation of PRDX enzymes remains catalytically inactive. The CDK- (cyclin-dependent kinases-) mediated phosphorylation of PRDX1, PRDX2, PRDX3, and PRDX4 at the conserved Thr⁸⁹ residue reduces peroxidase activity of peroxiredoxins [164]. Furthermore, Thr⁸⁹ phosphorylation abrogates enzymatic activity via disruption of the decameric conformation [165]. Multiple scientists suggested that the dimeric states of PRDX display reduced activity, compared to the decameric states [166–168]. Targeted PRDX C termini proteolysis suppresses peroxide-based inactivation, under high levels of peroxide. This is yet another proposed mechanism of peroxidase activity regulation [169].

4.5. Heme Oxygenase (HO). HO is an oxidase enzyme with varied function. In the process of hemoglobin catabolism, with sufficient molecular O₂ and reduced NADPH, HO promotes heme degradation to iron, carbon monoxide, and biliverdin. The two reported HO isoforms are HO-1 and HO-2, and they both express in the ER. HO-1 is a 32 kDa heat shock protein, and it is sensitive to a myriad of toxic stimuli, in locations, such as the lung [170, 171], liver [172, 173], and intestine [174–176]. Most inducers produce OS, including heme and heavy metals [177], hyperoxia [178], hypoxia [179], H₂O₂ [180], hyperthermia [181], and endotoxin [182]. HO-2 is a 36 kDa protein, and it is ubiquitously expressed in the brain and testis [183].

This review focuses on HO-1, which is mainly located in the intestine (Figure 1). HO-1 is a 288-residue protein [184, 185] composed mainly of α -helices, with heme in between the distal and proximal helices [186]. The conserved glycines associated with the distal helix facilitate flexibility, which

causes the two HO molecules in the crystallographic unit cell to be varied. In one HO, the active pocket remains fairly open, with loose distal helix-heme interaction. The corresponding HO forms tighter heme-distal helix connection. This, along with the elevated crystallographic thermal values, indicates that the distal helix flexibility promotes the opening and closing of the heme pocket to facilitate interaction with the heme substrate and simultaneously allow dissociation of the biliverdin product. Similar to cytochromes P450, HO also oxidizes an unstimulated carbon center, whereas P450 employs a cysteine thiolate heme ligand that critically regulates O₂ activation. HO is very similar to the globins in the O₂-heme iron ligation, induced by an axial histidine ligand [187, 188].

HO-1 expression is modulated transcriptionally via porphyrins, metals, progesterone, other molecules, and it is expressed under OS, ischemia, hypoxia, and other disease conditions [189]. The human HO-1 5' flanking region contains multiple regulatory elements [190], and thus far, transcriptional regulation appears to be the major form of HO-1 regulation by most, if not all, agents. HO-1 research currently focuses on the recognition and characterization of cis-acting DNA elements and their cognate binding proteins that carry out activation of gene transcription. In a majority of cases, these motifs are similar to or slightly differ from recognition sites for reported DNA-interacting proteins, namely, Fos/Jun (AP-1) and NF- κ B/Rel protein family, which are two primary OS-inducible TFs in mammalian cells [191].

5. Intestinal Reactive Species (RS)

Of note, the terminology ROS should be appropriately named using the particular chemical species under consideration. O₂ often reduces to free radicals (e.g., free electron like the O^{2•-} anion radical and the hydroxyl radical). In contrast, H₂O₂ is the product of two-electron reduction. Since it is not a radical, it is chemically stable. Electronic excitation often includes a single molecular O₂ and excited carbonyl compounds (i.e., nonradicals). Additional physiologically significant RS include chlorine and bromine species like hypohalous acids, hypochlorite, and chloramines. Free radicals, generated under both normal and pathological conditions, are extremely reactive and have an unsatisfied electron valence pair. These are very damaging to tissues, as is reported in cases of radiation, environmental chemical damage, and aging. Often, "free radicals" and "ROS" are utilized interchangeably. This may be correct in most cases, but, in certain instances, this terminology can be misleading.

O₂^{•-} is the most significant ROS, and it can produce other reactive O₂ intermediates. The inner mitochondrial membrane (IM) harbors a multitude of enzyme complexes commonly known as the mitochondrial respiratory chain (MRC). The MRC contains complexes I-IV (NADH-ubiquinone oxidoreductase, succinate dehydrogenase, ubiquinol-cytochrome c oxidoreductase, and cytochrome c oxidase (CCO)), coenzyme Q (CoQ), and a peripheral protein cytochrome c located on the surface of the IM. MRC complexes I and III release electrons that reduce molecular O₂ to form O₂^{•-} [192]. CCO (complex IV) is the last MRC-associated

enzyme to reduce O₂ to two H₂O molecules using a four-electron reduction [193]. Complex IV is not regarded as a physiologically significant ROS origin [194]. Instead, it was shown to serve as a mitochondrial antioxidant that oxidizes O₂^{•-} to O₂ [195]. In case of elevated cellular O₂, CCO is oxidized and uses NO. But, under reduced O₂ levels, NO accumulates within the cell [196].

Indeed, not all free radicals induce OS. In fact, OS is intricately linked to ROS. ROS is extremely reactive, and it is constantly generated via cellular respiration and various enzyme reactions. Among common ROS are as follows: O₂^{•-}, hydroxyl radicals ([•]HO), LOOHs, and reactive nonradical compounds like singlet O₂ (¹O₂), H₂O₂, and hypochlorous acid (HOCl) [197]. RNS includes radical compounds like [•]NO, nitrogen dioxide ([•]NO₂), and nonradical compounds like peroxynitrite (ONOO⁻) and dinitrogen trioxide (N₂O₃).

A majority of the above compounds have poor stability due to the unpaired electrons in their outer electron orbit. Upon ROS accumulation, chief cellular antioxidants like GSH and thioredoxin undergo altered redox states, thereby decreasing antioxidant defenses. Therefore, based on the above review of intestinal oxidoreductases, RS are classified in Table 3. RS are crucial for the maintenance of intestinal physiological activities, and this review will detail the significance of RS in intestinal OS.

6. The "Tai Chi" Theory of Intestinal Redox System

Oxidative stress is an imbalance between oxidants and antioxidants in favor of oxidants that leads to the disruption of redox signaling and/or molecular damage [198]. OS stratification, based on intensity, is as follows: basal, low, intermediate, and high intensity OS are generally abbreviated as BOS, LOS, IOS, and HOS [199]. BOS also represents physiological OS or oxidative eustress (OeS) [200]. Pathological OS is often termed as OS, but the limitation between OeS and OS is not clear. In fact, cellular H₂O₂ concentration of 0.1 μ M can be considered as OeS or OS in different cellular states [201].

Under BOS conditions, OS is so negligible that it cannot be measured using traditional approaches. Augmented ROS dosages can trigger LOS, in which case, both oxidatively modified structures and endpoint parameters like ROS-driven ROS-sensitive parameters can be measured. LOS may be divided into two components, increasing and decreasing, after it passes maximum. Upon further dosage increases, cells enter the IOS and then HOS stage. In the HOS, both measured function plateau, meaning that all available substrates become potentially oxidized, thus achieving a near maximum response. The redox enzyme regulation is critical for the above complex processes. The specific modulation of each enzyme was described in the previous paragraph, and the regulation mechanism of redox enzyme is summarized below.

6.1. The Thiol/Disulfide in Intestinal Redox Regulation. Under normal conditions, extracellular GSH concentrations remain quite scarce, other than in the intestinal lumen (60–300 μ M), where GSH levels are high, due to elevated levels in

TABLE 3: Reactive species in intestine.

	Free radicals	Nonradicals
Reactive oxygen species	Hydroxyl radical	Hydrogen peroxide
	Superoxides	Hypochlorous acid
		Lipid peroxides
	Singlet oxygen	Prostaglandin endoperoxides
Reactive nitrogen species		Electronically excited carbonyls
	Nitric oxide	Nitrate
		Peroxyxynitrite

the bile (1–2 mM in rat bile) [202] and dietary intake [203]. Luminal GSH catalyzes dietary disulfide reduction, peroxidized lipid metabolism, xenobiotic detoxification, and mucin oligomer assembly to maintain mucus fluidity [202, 204, 205]. Daily dietary lipid peroxide intake can reach around 1.4 mmol, with an 84 g fat intake [206]. Luminal and intracellular GSH strongly safeguards against dietary lipid peroxides [207]. In rats chronically fed with lipid peroxides, GSH supplementation protects against lipid peroxide-mediated suppression of mucosal proliferation [208]. Increasingly, scientists believe that in biological systems, the GSH/GSSG redox, in combination with Trx/TrxSS and Cys/CySS, forms distinct redox modulation nodes that regulate cell metabolism and growth [209]. Given that all redox couples exist without equilibrium, their function as an on-off sulfur switch supports the distinct modulation of a singular protein or protein sets during normal cellular function [210].

The Cys/CySS redox couple, with partial help from the GSH system, modulates the extracellular/luminal redox environment [211]. The plasma Cys/CySS and GSH/GSSG redox couples become displaced from equilibrium carrying Eh values strongly set at -80 mV and -140 mV, respectively [209, 212]. The true extracellular Cys and CySS concentrations are relatively low, at 40 μ M and 8 – 10 μ M, respectively, and are determined based on the Cys/CySS in the diet [213], GSH hydrolysis [214], thiol-disulfide exchange reactions [215], and Cys/CySS shuttle [216]. An oxidized plasma Cys/CySS redox state is strongly correlated with vascular diseases, such as diabetes, cardiovascular disease, and atherosclerosis [212]. Therefore, plasma Cys/CySS alterations may predict health and disease [217]. Luminal Cys/CySS maintains the thiol-disulfide redox states of extracellular proteins [218] and lumen [219]. In rat intestine, GSH hydrolysis, necessary for nutrient absorption [220] and mucus preservation [221], produces $\sim 40\%$ luminal Cys. The luminal thiol-disulfide redox status is modulated via the Cys/CySS shuttle [211] and includes luminal Cys export [219], GSSG reduction, and CySS synthesis [211], with subsequent CySS absorption [222], intracellular GSH-based CySS reduction, and Cys resecretion into the lumen. In polarized Caco-2 cells, Cys/CySS Eh at basal and apical surfaces are modulated at varying rates [223], suggesting stand-alone redox networks at corresponding polar membrane surfaces.

6.2. H_2O_2 in Intestinal Redox Regulation. H_2O_2 does not have charge and is, therefore, optimal for redox sensing

and signaling [224, 225]. Despite being known for extremely slow reactions with biomolecules (second-order rate constants approximately 1/M/s), H_2O_2 reacts well with certain residues, for instance, some cysteinyl residues in peroxidases or selenocysteinyl residues in GPXs (10^7 /M/s) [226]. Also, since H_2O_2 has a sluggish reaction, it is able to diffuse further from the production site to react with targets some distance away. In contrast, highly reactive oxidants like hydroxyl radical exhibit a more localized reaction.

Multiple studies suggested potential roles of thiol peroxidases as H_2O_2 sensors and transducers. H_2O_2 is a crucial member of redox networks [227]. For instance, peroxiredoxin-2 is a highly sensitive primary H_2O_2 receptor that particularly conveys oxidative equivalents to the redox-modulated TF STAT3 to generate a redox relay for the H_2O_2 redox network [228]. Another way of spatiotemporal modulation is the H_2O_2 -mediated hyperoxidation of peroxiredoxin cysteinyl residues to sulfinic acid. This, in turn, inactivates the peroxidase. This event produces a large buildup of H_2O_2 at target sites, which then facilitates oxidation of targeted proteins [229]. Sulfiredoxin reduces the hyperoxidized peroxiredoxins, thus closing the functional loop and restoring functionality [230]. Hence, when confined close to the physiological H_2O_2 concentration range (i.e., 10 nM) [231, 232], H_2O_2 acts as an appropriate secondary messenger in redox signaling. Based on the conclusions of two studies, an intact liver H_2O_2 production rate is around 50 nmol H_2O_2 per min per gram, which is about 2% of the entire O_2 uptake under steady conditions [232, 233].

6.3. The “Tai Chi” Theory Based on Intestinal Redox Regulation. There are many theories aimed at generalizing the function and regulation of the intestinal redox system, such as the redox species balance regulated by the intestinal oxidoreductases involves in various physiological functions including absorption and defense [234, 235]. But this “balance” cannot accurately describe the operational mode of the intestinal redox system. Firstly, each oxidoreductase primarily mediates its action via translational or posttranslational processing, which does not necessarily maintain the balance of enzymatic activities. Additionally, the way of the oxidoreductase products, particularly thiol/disulfide or H_2O_2 , maintaining the redox balance is not simply by down-regulating or upregulating its level or activity, otherwise known as “dynamic balance” or “homeostasis” which is more appropriate. Moreover, given the above factors, at




FIGURE 3: The intestinal oxidation-reduction (redox) system “Tai Chi” in normal physiological function. To support normal physiological function, the level of redox species was maintained in a certain limitation using subtle and complex regulatory methods, including local (induced by the oxidoreductases in different cell, tissue, and organ location) and global (induced by the products of oxidoreductases inside and outside the cell, even inside and outside the intestine) horizontal regulation. Additionally, the intestinal physiological function mainly includes the absorption of nutrients (water with the white point and inorganic salt with the black point) and the defense against pathogenic microorganisms.

cellular, tissue, and whole level, the “balance” alone cannot appropriately explain the mechanism of the intestinal redox system under physiological or pathological status.

Therefore, with reference to the concept of ancient Chinese medicinal theory, we proposed the “Tai Chi” theory of the intestinal redox system to explain the intestinal redox system (Figures 2 and 3). The “balance” theory is inexact that the level of redox species maintains the intestinal redox balance via a “down or up” regulation. The intestinal redox system supports the physiological function by a subtle and complex regulatory ways, including local (induced by the oxidoreductases in different cell, tissue, and organ locations) and global (induced by the products of oxidoreductases inside and outside the cell, even inside and outside the intestine) horizontal regulation. We summarized the regulation and function of redox system as the “Tai Chi” theory for its mutually reinforced and neutralized elements and maintenance of homeostasis with a certain amount of redox species.

7. Overview of The Intestinal RedoxSystem in CIM

Our article selection process is detailed in supplemental information. Based on the module and search string in EMBASE (Table S1), PubMed (Table S2), and Web of Science (Table S3), we established the retrieval strategy of the above respective databases (Table S4). Overall, 51 articles were selected from the date of inception till July 31, 2021 (Figure 4). Using literature analysis, we revealed that ROS was critical for CIM pathology, and it was induced by only five chemotherapeutic drugs, namely, methotrexate (MTX), 5-fluorouracil (5-FU), cisplatin, irinotecan (CPT-11), and oxaliplatin.

The existing literature and mainstream academic view is that ROS is produced rapidly in the initial stage as the chemotherapy drugs cause direct damage to intestinal

mucosa cells, thus resulting in necrosis, mitochondrial dysfunction, and further ROS generation. Through our review of the intestinal redox system, we revealed that the intestinal redox enzyme system is very complex and is regulated by multiple factors. Thus, ROS production is not limited to the early stage but is present throughout the entire course of CIM. Therefore, the redox system is involved in all stages of CIM.

Given that some chemotherapeutic drugs produce ROS using different redox enzymes, we first elaborated the mechanism of oxidoreductase and its modulation by chemotherapeutic drugs, in this review. In our analysis, we primarily selected articles that examined alterations in the redox enzyme level or activity as indicators of CIM severity. To circumvent limitations based on our literature selection, we also explored the structural and regulation characteristics of intestinal oxidoreductase to further elucidate their significance in CIM pathogenesis.

8. Oxidoreductases in CIM

8.1. 5-Fluorouracil (5-FU)

(5-) FU is a highly prevalent chemotherapeutic medication for the management of multiple forms of cancer [236]. Unfortunately, approximately 50–80% 5-FU consumers eventually develop mucositis and discontinue chemotherapy [237, 238]. 5-FU also causes diarrhea likely via a multifactorial network involving acute harm to the mucosal intestine (such as intestinal epithelial loss, superficial necrosis, and inflamed bowel wall), thereby causing an imbalance between absorption and secretion within the small intestine [239]. In a retrospective study, it was observed that 5-FU elevates NOS and MPO, while reducing CAT, SOD, GPX, PRDX, and HO (Table 4). This, in turn, enhances $O^{2\bullet-}$, H_2O_2 , lipid




FIGURE 4: A flow diagram of the identification of articles included in this review.

peroxides, nitrate, and protein carbonyls, while diminishing GSH and NO. 5-FU also triggers an excessive NF- κ B production, which modulates oxidoreductases to regulate CIM progression [240–243]. In 5-FU-mediated CIM, enteric glial cells secrete S100B to activate neuronal NF- κ B axis in a RAGE-reliant fashion. This triggers glial cell to secrete iNOS-based NO and OS [240]. Other researchers reported that 5-FU enhances NF- κ B levels [241–243], which is the sole basis of the CIM-based oxidoreductases regulation. There is conclusive evidence that MPO (via TLR-4/NF- κ B) [244], HO (NF- κ B/Rel) [191], and CAT (AKT/NF- κ B) [84, 245] regulation occurs via the intestinal NF- κ B-related pathway.

Another significant mechanism underlying 5-FU-based CIM is the Nrf pathway-mediated regulation of HO [246, 247]. 5-FU activates NF-E2-related factor 2 (Nrf2), which decouples from the actin-related Keap1 protein to transfer to the nucleus, whereby it promotes HO-1 cytoprotective gene transcription [248, 249]. However, the mechanism of ROS-scavenging oxidoreductase HO-1 in CIM is controversial. HO-1 was shown to be either up- [247] or downregulated [250] in 5-FU-based CIM, and this may be due to a

compensatory mechanism. In normal physiological conditions, cells balance excessive ROS production with ROS elimination via scavenging systems like intracellular redox-balancing gene HO-1, phase II detoxifying gene quinone oxidoreductase-1 (NQO-1), and genes encoding transporters (multidrug-resistant proteins) [251]. A majority of the above genes possess an enhancer sequence termed as the antioxidant response element [252–254], which is activated by the TF Nrf2. Considering the physiological roles of these are-containing genes, it is possible that Nrf2 target gene activation will likely enhance detoxication of xenobiotics like chemotherapeutic drugs, in order to protect cells from ROS-induced apoptosis [255].

5-FU is highly efficacious in boosting CIM-induced apoptosis. This is carried out via downregulation of Bcl-2 expression while upregulating Bax levels [242, 250, 256–258]. Apoptosis is a systematic process involving multiple genes like caspase-3, Bcl-2, and Bax. Bcl-2 strongly modulates apoptotic signaling and is, therefore, referred to as a survival-promoting protein. In contrast, Bax is regarded as the opposite of Bcl-2; thus, it is a proapoptotic protein [259]. Additionally, suppressing the ATF4/Chop/Bcl-2/Bax network inhibits the activation of SOD, GPX, and CAT. In ATF4-KD mice, for example, both intestinal GPX and CAT levels were markedly elevated, relative to AFT-WT mice [260].

TABLE 4: Oxidoreductases and redox species in CIM.

	5-FU	MTX	CPT-11	Cisplatin	Oxaliplatin
Oxidoreductases					
NADPH oxidase			↑[297]		
Xanthine dehydrogenase		↑[298]			
Nitric oxide synthase	↑[240, 241, 250, 299]				↑[300]
Myeloperoxidase	↑[241, 246, 257, 258, 299, 301–309]	↑[269, 298, 310]	↑[285, 297, 311–313]		
Catalase	↓[239, 242, 247, 304, 314–316]	↓[263, 310]	↑[312]		
Superoxide dismutase	↓[239, 242, 246, 247, 257, 304, 317]	↓[263, 298, 310, 318]	↓[285]	↓[319, 320]	↓[300]
Glutathione peroxidase	↓[242, 257, 310]	↓[263, 310, 318]	↓[285]	↓[319, 320]	
Peroxiredoxin	↓[265]				
Heme oxygenase	↓[250] ↑[247]		↓[285]		
Redox species					
ROS	↑[242, 243, 246, 250, 256, 321]	↑[263, 298, 322, 323]	↑[311, 312]		
Superoxides	↑[246]				
Nitric oxide	↑[247, 257]		↑[285]		↑[300]
Hydrogen peroxide	↑[302, 304]		↑[324]		
Peroxynitrite		↑			
Lipid peroxides	↑[239, 241, 247, 257, 258, 301–304, 308, 314, 315, 317, 325, 326]	↑[263, 269, 270, 310, 318]	↑[285, 297, 311–313, 325]	↑[319, 320, 327]	↑[300]
Nitrate	↑[240, 308, 314]	↑[273]	↑[312]		
Protein carbonyls	↑[239]	↑[310]		↑[327]	
GSH	↓[242, 247, 257, 301, 303, 307, 314]	↓[269, 270, 298]	↓[297, 311–313, 325]	↓[319, 320, 327]	↓[300]

8.2. *Methotrexate (MTX)*. MTX is a folic acid counterpart that suppresses dihydrofolate reductase enzyme activity. It is a highly efficacious chemotherapeutic drug against acute leukemia, trophoblastic disease, and intraosseous sarcoma, and it was recently employed as an antirheumatic drug [254]. MTX induces GI toxicity that manifests as diarrhea, nausea, and reduced nutrient absorption. CIM is highly prevalent in MTX therapy. The MTX-induced CIM causes villus atrophy or crypt loss, as evidenced by histology [261–264]. Based on a retrospective investigation, MTX enhances xanthine dehydrogenase and MPO, while diminishing CAT, SOD, and GPX activity (Table 4). This results in the augmentation of peroxynitrite, lipid peroxides, nitrate, and protein carbonyls, while reducing GSH activity.

MTX also induces mitochondrial dysfunction and respiratory chain defects during CIM [265–267]. It triggers enterocytic ultraconformational alterations like swollen mitochondria, excessive crista disruption, altered mitochondrial morphology, ER and GA dilatation/cytoplasmic vacuolation, and microvilli degeneration and fragmentation. In a study examining MTX effects on treated cells, the mitochondrial damage was obvious after only 6 h, and the severity of damage only increased with time. The mitochondria were swollen after 6 h of MTX therapy, and cristae were disrupted after 12 h. The crista disruption

was more extensive at 24 h, with complete crista dissolution at 48 h. The ER and GA dilatations were regarded as degenerative vacuolar appearance at 24 h following MTX therapy. Based on the Trump-defined classification of mitochondrial injury (MI), the enterocyte MI score of MTX-administered rats was >4, suggesting considerable MI that can initiate the apoptotic and/or necrotic process in enterocytes. MTX drastically decreases (>70%) ETC complex II and IV activities, without any change to complex I and III activities. Hence, it is not difficult to understand that the function of redox enzymes, including SOD and GPX, is primarily located within the mitochondria, and it decreases with mitochondrial dysfunction.

MTX strongly upregulates TNF- α transcript and protein expressions during CIM [268–270]. In turn, TNF- α induces XDH activity in renal epithelial cells [271] and RAW 264.7 [272]. Moreover, human XDH, which is ubiquitous in the liver and intestine, is modulated by multiple promoter element-binding factors [40]. To identify relevant human XDH gene 5'-flanking region promoter elements, one study examined the 200 base pair sequence of the 5'-flanking region. The scientists identified candidate docking regions for factors associated with inflammation and acute phase response. In particular, they demonstrated four CCAAT/enhancer protein interacting sites, three IL-6 RE, one NF- κ B site, possible




FIGURE 5: The intestinal oxidation-reduction (redox) “Tai Chi” system in CIM pathogenesis. MTX, 5-FU, cisplatin, CPT-11, and oxaliplatin induced high levels of O_2^- , H_2O_2 , NO, and HA via regulation of oxidoreductases, which disrupted the balance of intestinal redox “Tai Chi” system, and resulted in apoptosis and inflammation of the intestine, which contributed to the pathogenesis of CIM.

TNF- α , interferon- γ , and interleukin-1 RE. Regrettably, even though we can infer that the activity of XDH, ROS, and TNF is increased in MTX-induced CIM, the direct or indirect relationship between them still remains under investigation.

MTX enhances PARP levels in the duodenum and ileum [273], with the villi and crypts exhibiting high intensity focal expression. In contrast, the jejunum rarely exhibited this level of expression. The Alu receptor RE (AluRRE) that is upstream of the MPO gene is a standard member of the principal Alu subcategory, and it carries four hexamer half sites linked to the consensus AGGTCA, and it is identified by members of the nuclear receptor superfamily of ligand-dependent TFs [79, 80, 274]. The hexamers form direct repeats with spacings of 2, 4, and 2 bp [275]. PPARc–RXR heterodimers interact with the third and fourth hexamers, and the PPARc ligands markedly accelerate human MPO production in MCSF-M/ (~20-fold), while inhibiting MPO in GMCSF-M/ (~20-fold) [80]. Nevertheless, MTX increases MPO, but whether this involves PARP activation remains to be seen.

MTX also interacts with histone to form an MTX-protein complex that diminishes histone acetyltransferases (HAT) activity [276]. MTX was shown to bind Lys⁹ on the histone stick model and the Lys³⁷, and Arg⁴⁰-associated histones showed the strongest binding between medication and protein. Additionally, the protein complex-based MTX-driven reduction in histone acetylation pattern also reduces HAT activity. Furthermore, acetylation on histone induces higher CAT mRNA expression [277], which, in a feedback loop, induces MTX-driven downregulation of CAT via acetylation.

8.3. Others. Cisplatin is highly efficacious and, therefore, commonly employed in cancer therapy. However, it is known to elicit numerous adverse effects [278–280], including CIM [281, 282]. The structural CIM presentations include loss of crypt and villus atrophy. Functionally, CIM presents as impairments in absorption and barrier integrity [281, 283]. A retrospective analysis revealed that cisplatin and oxaliplatin drastically increased NOS, while decreasing CAT, SOD, and GPX. This, in turn, enhanced NO, lipid peroxides, and protein carbonyls, while reducing GSH levels. Similar to camptothecin, irinotecan hydrochloride (CPT-

11) is an antiproliferative medication used to manage multiple forms of solid tumors. But, CPT-11 is also associated with adverse effects like CIM [284]. The CPT-11-induced intestinal damage is characterized by enhanced jejunal crypt apoptosis and destruction of colon villi, while decreasing goblet cells. Owing to these changes, patients often experience bloating, abdominal pain, diarrhea, and weight loss. Based on our retrospective analysis of relevant literature, CPT-11 upregulates NOX and MPO, while downregulating CAT, SOD, GPX, and HO, which results in increased levels of NO, H_2O_2 , and lipid peroxides, nitrate, while decreasing levels of GSH and NO (Table 4). Similar to 5-FU, CPT-11 downregulates HO via the Keap-1/Nrf-2 pathway [285]. The TF Nrf2 is a critical redox switch that modulates levels of antioxidant and protective enzymes. Moreover, the enzyme activities and sensitivities are modulated by the ubiquitin ligase adaptor Kelch-like ECH-associated protein- (Keap-) 1 [286]. Finally, it is unique that CPT-11 decreases HO expression thus inactivating the Keap-1/Nrf-2 pathway.

9. RS in CIM

The core of the pathological mechanism of CIM is the cascade amplification of inflammatory factors. Therefore, some scholars classified this as a special type of intestinal inflammatory disease and provided theoretical evidences and clues to further examine the networks related to RS in CIM.

9.1. The Role of RS in CIM-Based Inflammation. Five chemotherapeutic drugs induce ROS activation. Elevated ROS levels phosphorylate I- κ B α to initiate destruction of the protein, thereby releasing NF- κ B, which then relocates to the nucleus [287]. This ROS/NF- κ B self-sustaining modulatory network likely contributes to the continuation and aggravation of chronic inflammation [288, 289]. NF- κ B activation triggers the expression of some 200 genes, a majority of which regulate mucosal toxicity [288]. Genetic activation via chemotherapy-triggered TF activation was shown to augment proinflammatory cytokines TNF- α , IL-1 β , and IL-6 production [4]. Moreover, these proteins accumulate in the mucosa. The increase in proinflammatory cytokines likely initiates the early destruction of connective tissue and

TABLE 5: The treatment strategies to CIM in studies included in the review.

Traditional Chinese medicine	Nature products	Synthesis compound	Food extract	Probiotics	Vitamin	Amino acid	Others
Carboxymethyl pachyman [242] Saikosaponin-A [247] Aquilariae Lignum Resinatum [317] Rutin [301] Trolox [307] Taurine Lutein Rehmannia glutinosa Libosch [270] Gegen Qinlian decoction [285] Luteolin [312]	FITOPROT [243] Diadzein [314] Cashew Gum [303] Proanthocyanidins [256] Ursodeoxycholic acid	Apolipoprotein mimetic peptide [299] MS-SOD [246]	Pomegranate Juice [250] Açaí	Fructo-oligosaccharides Lactobacillus UFMG A-905 [328] Exopolysaccharide [257]	Vitamin C Vitamin E [241]	L-Arginine L- Citrulline	Melatonin [273] Ozone
MTX	Salecan [263]	Anakinra [269] Prostaglandin E [323]	Royal jelly [264]				
CPT-11	FITOPROT [313] Proanthocyanidins	Nanocomposite Fullerol [311]	Coffee ingredients	UFMG A-905			
Cisplatin		Se@Albumin nanoparticles [319]			Vitamin	D- Methionine	
Oxaliplatin	Magnolol						




FIGURE 6: The mechanism of CIM treatment strategies in studies included in this review. The treatment strategies can be divided into 3 categories, according to the targets: proanthocyanidins, UFMG A-905, rutin, salean, melatonin, and magnolol target redox and inflammation; lutein and pomegranate juice target redox and apoptosis; and vitamin E and FITOPROT target redox, inflammation, and apoptosis.

endothelium, thereby enhancing mesenchymal–epithelial signaling, while decreasing epithelial oxygenation and, eventually, developing epithelial basal-cell death and injury (Figure 5).

9.2. The RS-Mediated Apoptosis in CIM. NO triggers intestinal apoptosis, which contributes to CIM pathology. It was reported that enhanced iNOS activity and immunoreactivity to 3-nitrotyrosine coincided perfectly with areas of intestinal necrosis or apoptosis. Hence, it is very likely that NO causes enterocytic apoptosis [290]. Multiple reports indicate that the mitochondria are critical for cell apoptosis. Mitochondrial cytochrome c secretions, along with the membrane depolarization, dominate the early stages of apoptosis. Furthermore, cytochrome c directly activates caspase-3 [290]. Richter [291] revealed that a reduction in cellular adenosine triphosphate (ATP) concentration triggers apoptosis. However, maintaining the mitochondrial membrane potential (i.e., the driving force for ATP production) prevents apoptosis, and dysregulating it releases proapoptotic factors. There is evidence that NO can directly alter mitochondrial membrane permeability to promote apoptosis. Moreover, the NO effects were abrogated using specific inhibitors of mitochondrial permeability transition [292].

LOOH is yet another RS that triggers apoptosis of human colonic CaCo-2 cells using redox shifts [293]. Using even subtoxic LOOH concentrations enhances CaCo-2 cell apoptosis. This LOOH-triggered apoptosis strongly correlates with marked reductions in the GSH-to-oxidized glutathione (GSH/GSSG) ratio, which typically precedes DNA fragmentation. GSH oxidation by the thiol oxidant diamide markedly diminishes cellular GSH, as well as the GSH/GSSG ratio, and it correlates with caspase-3 activation and PARP

cleavage. This confirms a temporal relationship between cellular redox imbalance and apoptotic cellular death. These kinetic investigations further revealed that the oxidant-mediated early redox alteration is a primary inciting event in the apoptotic cascade. Once initiated, the redox balance recovery fails to protect against apoptosis of CaCo-2 cells. Taken together, the subtoxic LOOH levels dysregulate intestinal redox homeostasis, and this eventually leads to cell apoptosis.

10. The Intestinal Redox Regulation in CIM

It is interesting that the GSH/GSSG balance is a critical factor in the modulation of the intestinal redox system, and it is also involved in the intestinal apoptotic pathway [293]. An alteration of the GSH/GSSG ratio is intricately linked to caspase-3 activation. This strongly correlates dysregulated redox homeostasis to apoptosis initiation. Scientists observed a comparable relationship between GSH oxidation and apoptosis in fibroblast cells, upon serum withdrawal. Moreover, the BOS-induced loss of cellular GSH, without alteration to the GSH/GSSG ratio, displayed no initiation of cell apoptosis. Instead, cell apoptosis was closely related to enhanced GSSG, and not GSH. Furthermore, multiple studies indicate an influence of H₂O₂ in intestinal apoptosis as well [294, 295].

11. The Intestinal Redox System and Its Role in CIM Treatment Strategies

There are 39 treatment strategies from the studies included in this review. These strategies can be further divided into 7 classes: traditional Chinese medicine (TCM), nature products, synthesis compound, food extract, probiotics, vitamin, amino

acid, and others (Table 5). Unfortunately, all studies used animal models or cells as research objects and were not clinical studies. This also indicates that these treatment strategies have certain limitations. Most of them regard the intestinal redox system as the effect indicator of CIM, without in-depth discussion of the mechanism whereby the redox reaction is influenced and plays a role in the treatment of CIM.

Based on our review of relevant literature discussing the mechanism of various CIM treatment strategies, these treatment strategies can be divided into 3 categories, according to the targets: proanthocyanidins, UFMG A-905, rutin, salean, melatonin, and magnolol target redox and inflammation; lutein and pomegranate juice target redox and apoptosis; and lastly, vitamin E and FITOPROT target redox, inflammation, and apoptosis (Figure 6). As we discussed earlier, NF- κ B (in inflammation) and caspase-3 (in apoptosis) are the key target molecules influenced by the intestinal redox system, and the above treatments relieve CIM mainly via NF- κ B and caspase-3 regulation. However, it is worth noting that the experimental evidence of the studies is not sufficient, particularly in terms of the validation of the pathway, and there is a lack of omics research as well. It is encouraging that there are more and more studies involving TCM, which also applies our “Tai Chi” theory to elaborate the intestinal redox system and its role in the short-term treatment strategies involving CIM.

12. Conclusion

Based on the elaboration of the intestinal redox enzyme and its regulation mechanism, considering that the regulation of the OS level is not simply described as “increased” or “decreased,” and it is observed both inside and outside the cell, the intestine, and even the body, we preliminarily proposed the intestinal redox “Tai Chi” theory and attempted to reveal the role of OS events in the pathogenesis of CIM. However, current studies involving CIM employed oxidoreductases and reactive species as evaluation index of disease, which is inappropriate, as per our review. Moreover, the intestinal redox system participates in the pathogenesis and affects the prognosis of CIM, which is still worthy of in depth study.

Data Availability

The data used to support this study are included within the article.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Authors' Contributions

Qing-Qing Yu and Heng Zhang contributed equally to this work.

Acknowledgments

This work was supported by the Bethune Charitable Foundation (No.: B-19-H-20200622)/Scientific Research Foundation of Shandong Medical Association (No.: YXH2020ZX053)/National Natural Science Foundation of Shandong (No.: ZR201911070207) and was sponsored by Doctoral Fund of Jining No. 1 People's Hospital (2021-BS-002).

Supplementary Materials

Using a similar modular search strategy described in Ranna et al. [296], the article selection process of the review is detailed in supplemental material. (*Supplementary Materials*)

References

- [1] R. V. Lalla, J. Bowen, A. Barasch et al., “MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy,” *Cancer*, vol. 120, no. 10, pp. 1453–1461, 2014.
- [2] D. E. Peterson, C. B. Boers-Doets, R. J. Bensadoun, J. Herrstedt, and ESMO Guidelines Committee, “Management of oral and gastrointestinal mucosal injury: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up†,” *Annals of Oncology*, vol. 26, Supplement 5, pp. v139–v151, 2015.
- [3] M. Cinausero, G. Aprile, P. Ermacora et al., “New frontiers in the pathobiology and treatment of cancer regimen-related mucosal injury,” *Frontiers in Pharmacology*, vol. 8, p. 354, 2017.
- [4] S. T. Sonis, “The pathobiology of mucositis,” *Nature Reviews Cancer*, vol. 4, no. 4, pp. 277–284, 2004.
- [5] N. Al-Dasooqi, S. T. Sonis, J. M. Bowen et al., “Emerging evidence on the pathobiology of mucositis,” *Support Care Cancer*, vol. 21, no. 7, pp. 2075–2083, 2013.
- [6] Y. Z. A. Van Sebille, R. Stansborough, H. R. Wardill, E. Bateman, R. J. Gibson, and D. M. Keefe, “Management of mucositis during chemotherapy: from pathophysiology to pragmatic therapeutics,” *Current Oncology Reports*, vol. 17, no. 11, p. 50, 2015.
- [7] J. W. Denham and M. Hauer-Jensen, “The radiotherapeutic injury - a complex 'wound',” *Radiotherapy and Oncology*, vol. 63, no. 2, pp. 129–145, 2002.
- [8] B. Bánfi, A. Maturana, S. Jaconi et al., “A mammalian H⁺ channel generated through alternative splicing of the NADPH oxidase homolog *NOX-1*,” *Science*, vol. 287, no. 5450, pp. 138–142, 2000.
- [9] H. Kikuchi, M. Hikage, H. Miyashita, and M. Fukumoto, “NADPH oxidase subunit, gp91^{phox} homologue, preferentially expressed in human colon epithelial cells,” *Gene*, vol. 254, no. 1-2, pp. 237–243, 2000.
- [10] Y. A. Suh, R. S. Arnold, B. Lassegue et al., “Cell transformation by the superoxide-generating oxidase Mox1,” *Nature*, vol. 401, no. 6748, pp. 79–82, 1999.
- [11] M. D. Bates, C. R. Erwin, L. P. Sanford et al., “Novel genes and functional relationships in the adult mouse gastrointestinal tract identified by microarray analysis,” *Gastroenterology*, vol. 122, no. 5, pp. 1467–1482, 2002.

- [12] I. Szanto, L. Rubbia-Brandt, P. Kiss et al., "Expression of NOX1, a superoxide-generating NADPH oxidase, in colon cancer and inflammatory bowel disease," *The Journal of Pathology*, vol. 207, no. 2, pp. 164–176, 2005.
- [13] M. Geiszt, K. Lekstrom, S. Brenner et al., "NAD(P)H oxidase 1, a product of differentiated colon epithelial cells, can partially replace glycoprotein 91phox in the regulated production of superoxide by phagocytes," *Journal of Immunology*, vol. 171, no. 1, pp. 299–306, 2003.
- [14] R. A. El Hassani, N. Benfares, B. Caillou et al., "Dual oxidase2 is expressed all along the digestive tract," *American Journal of Physiology, Gastrointestinal and Liver Physiology*, vol. 288, no. 5, pp. G933–G942, 2005.
- [15] M. Geiszt, J. Witta, J. Baffi, K. Lekstrom, and T. L. Leto, "Dual oxidases represent novel hydrogen peroxide sources supporting mucosal surface host defense," *The FASEB Journal*, vol. 17, no. 11, pp. 1502–1504, 2003.
- [16] C. Dupuy, M. Pomerance, R. Ohayon et al., "Thyroid oxidase (THOX2) gene expression in the rat thyroid cell line FRTL-5," *Biochemical and Biophysical Research Communications*, vol. 277, no. 2, pp. 287–292, 2000.
- [17] R. K. Ambasta, P. Kumar, K. K. Griendling, H. H. H. W. Schmidt, R. Busse, and R. P. Brandes, "Direct Interaction of the Novel Nox Proteins with p22phox Is Required for the Formation of a Functionally Active NADPH Oxidase," *The Journal of Biological Chemistry*, vol. 279, no. 44, pp. 45935–45941, 2004.
- [18] M. Janiszewski, L. R. Lopes, A. O. Carmo et al., "Regulation of NAD(P)H Oxidase by Associated Protein Disulfide Isomerase in Vascular Smooth Muscle Cells*," *The Journal of Biological Chemistry*, vol. 280, no. 49, pp. 40813–40819, 2005.
- [19] X. L. Cui, D. Brockman, B. Campos, and L. Myatt, "Expression of NADPH oxidase isoform 1 (Nox1) in human placenta: involvement in preeclampsia," *Placenta*, vol. 27, no. 4-5, pp. 422–431, 2006.
- [20] Y. Kuwano, T. Kawahara, H. Yamamoto et al., "Interferon-gamma activates transcription of NADPH oxidase 1 gene and upregulates production of superoxide anion by human large intestinal epithelial cells," *American Journal of Physiology. Cell Physiology*, vol. 290, no. 2, pp. C433–C443, 2006.
- [21] A. C. Brewer, E. C. Sparks, and A. M. Shah, "Transcriptional regulation of the NADPH oxidase isoform, Nox1, in colon epithelial cells: role of GATA-binding factor(s)," *Free Radical Biology & Medicine*, vol. 40, no. 2, pp. 260–274, 2006.
- [22] X. De Deken, D. Wang, J. E. Dumont, and F. Miot, "Characterization of ThOX Proteins as Components of the Thyroid H₂O₂-Generating System," *Experimental Cell Research*, vol. 273, no. 2, pp. 187–196, 2002.
- [23] S. Morand, M. Chaaraoui, J. Kaniewski et al., "Effect of iodide on nicotinamide adenine dinucleotide phosphate oxidase activity and Duox2 protein expression in isolated porcine thyroid follicles," *Endocrinology*, vol. 144, no. 4, pp. 1241–1248, 2003.
- [24] S. Morand, D. Agnandji, M. S. Noel-Hudson et al., "Targeting of the Dual Oxidase 2 N-terminal Region to the Plasma Membrane*," *The Journal of Biological Chemistry*, vol. 279, no. 29, pp. 30244–30251, 2004.
- [25] R. Takeya, N. Ueno, K. Kami et al., "Novel Human Homologues of p47^{phox} and p67^{phox} Participate in Activation of Superoxide-producing NADPH Oxidases," *The Journal of Biological Chemistry*, vol. 278, no. 27, pp. 25234–25246, 2003.
- [26] M. T. Quinn, T. Evans, L. R. Loetterle, A. J. Jesaitis, and G. M. Bokoch, "Translocation of Rac correlates with NADPH oxidase activation. Evidence for equimolar translocation of oxidase components," *The Journal of Biological Chemistry*, vol. 268, no. 28, pp. 20983–20987, 1993.
- [27] F. B. Wientjes, J. J. Hsuan, N. F. Totty, and A. W. Segal, "p40^{phox}, a third cytosolic component of the activation complex of the NADPH oxidase to contain src homology 3 domains," *The Biochemical Journal*, vol. 296, no. 3, pp. 557–561, 1993.
- [28] M. Geiszt, K. Lekstrom, J. Witta, and T. L. Leto, "Proteins Homologous to p47^{phox} and p67^{phox} Support Superoxide Production by NAD(P)H Oxidase 1 in Colon Epithelial Cells*," *The Journal of Biological Chemistry*, vol. 278, no. 22, pp. 20006–20012, 2003.
- [29] T. Ueyama, M. Geiszt, and T. L. Leto, "Involvement of Rac1 in activation of multicomponent Nox1- and Nox3-based NADPH oxidases," *Molecular and Cellular Biology*, vol. 26, no. 6, pp. 2160–2174, 2006.
- [30] G. Cheng, B. A. Diebold, Y. Hughes, and J. D. Lambeth, "Nox1-dependent Reactive Oxygen Generation Is Regulated by Rac1," *The Journal of Biological Chemistry*, vol. 281, no. 26, pp. 17718–17726, 2006.
- [31] H. Sumimoto, K. Miyano, and R. Takeya, "Molecular composition and regulation of the Nox family NAD(P)H oxidases," *Biochemical and Biophysical Research Communications*, vol. 338, no. 1, pp. 677–686, 2005.
- [32] K. Miyano, N. Ueno, R. Takeya, and H. Sumimoto, "Direct Involvement of the Small GTPase Rac in Activation of the Superoxide-producing NADPH Oxidase Nox1," *The Journal of Biological Chemistry*, vol. 281, no. 31, pp. 21857–21868, 2006.
- [33] P. Pacher, A. Nivorozhkin, and C. Szabó, "Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol," *Pharmacological Reviews*, vol. 58, no. 1, pp. 87–114, 2006.
- [34] M. G. Battelli, E. D. Corte, and F. Stirpe, "Xanthine oxidase type D (dehydrogenase) in the intestine and other organs of the rat," *The Biochemical Journal*, vol. 126, no. 3, pp. 747–749, 1972.
- [35] C. A. Pritsos, "Cellular distribution, metabolism and regulation of the xanthine oxidoreductase enzyme system," *Chemico-Biological Interactions*, vol. 129, no. 1-2, pp. 195–208, 2000.
- [36] M. G. Battelli, A. Bolognesi, and L. Polito, "Pathophysiology of circulating xanthine oxidoreductase: new emerging roles for a multi-tasking enzyme," *Biochimica et Biophysica Acta*, vol. 1842, no. 9, pp. 1502–1517, 2014.
- [37] R. Harrison, "Structure and function of xanthine oxidoreductase: where are we now?," *Free Radical Biology and Medicine*, vol. 33, no. 6, pp. 774–797, 2002.
- [38] T. Nishino, K. Okamoto, B. T. Eger, E. F. Pai, and T. Nishino, "Mammalian xanthine oxidoreductase - mechanism of transition from xanthine dehydrogenase to xanthine oxidase," *The FEBS Journal*, vol. 275, no. 13, pp. 3278–3289, 2008.
- [39] Y. Yamaguchi, T. Matsumura, K. Ichida, K. Okamoto, and T. Nishino, "Human xanthine oxidase changes its substrate specificity to aldehyde oxidase type upon mutation of amino acid residues in the active site: roles of active site residues in binding and activation of purine substrate," *Journal of Biochemistry*, vol. 141, no. 4, pp. 513–524, 2007.
- [40] P. Xu, T. P. Huecksteadt, and J. R. Hoidal, "Molecular cloning and characterization of the human xanthine dehydrogenase gene (XDH)," *Genomics*, vol. 34, no. 2, pp. 173–180, 1996.

- [41] W. B. Poss, T. P. Huecksteadt, P. C. Panus, B. A. Freeman, and J. R. Hoidal, "Regulation of xanthine dehydrogenase and xanthine oxidase activity by hypoxia," *The American Journal of Physiology*, vol. 270, 6 Part 1, pp. L941–L946, 1996.
- [42] N. Linder, E. Martelin, R. Lapatto, and K. O. Raivio, "Post-translational inactivation of human xanthine oxidoreductase by oxygen under standard cell culture conditions," *American Journal of Physiology. Cell Physiology*, vol. 285, no. 1, pp. C48–C55, 2003.
- [43] L. S. Terada, D. Piermattei, G. N. Shibao, J. L. McManaman, and R. M. Wright, "Hypoxia regulates xanthine dehydrogenase activity at pre- and posttranslational levels," *Archives of Biochemistry and Biophysics*, vol. 348, no. 1, pp. 163–168, 1997.
- [44] E. E. Kelley, T. Hock, N. K. H. Khoo et al., "Moderate hypoxia induces xanthine oxidoreductase activity in arterial endothelial cells," *Free Radical Biology & Medicine*, vol. 40, no. 6, pp. 952–959, 2006.
- [45] K. Nichols, W. Staines, and A. Krantis, "Nitric oxide synthase distribution in the rat intestine: a histochemical analysis," *Gastroenterology*, vol. 105, no. 6, pp. 1651–1661, 1993.
- [46] K. Nichols, W. Staines, S. Rubin, and A. Krantis, "Distribution of nitric oxide synthase activity in arterioles and venules of rat and human intestine," *The American Journal of Physiology*, vol. 267, 2 Part 1, pp. G270–G275, 1994.
- [47] E. Gochman, J. Mahajna, P. Shenzer et al., "The expression of iNOS and nitrotyrosine in colitis and colon cancer in humans," *Acta Histochemica*, vol. 114, no. 8, pp. 827–835, 2012.
- [48] W. K. Alderton, C. E. Cooper, and R. G. Knowles, "Nitric oxide synthases: structure, function and inhibition," *The Biochemical Journal*, vol. 357, no. 3, pp. 593–615, 2001.
- [49] L. J. Roman, P. Martásek, and B. S. Masters, "Intrinsic and extrinsic modulation of nitric oxide synthase activity," *Chemical Reviews*, vol. 102, no. 4, pp. 1179–1190, 2002.
- [50] E. D. Garcin, C. M. Bruns, S. J. Lloyd et al., "Structural Basis for Isozyme-specific Regulation of Electron Transfer in Nitric-oxide Synthase," *The Journal of Biological Chemistry*, vol. 279, no. 36, pp. 37918–37927, 2004.
- [51] C. J. Lowenstein and E. Padalko, "iNOS (NOS2) at a glance," *Journal of Cell Science*, vol. 117, no. 14, pp. 2865–2867, 2004.
- [52] B. A. Maron, S. S. Tang, and J. Loscalzo, "S-nitrosothiols and the S-nitrosoproteome of the cardiovascular system," *Antioxidants & Redox Signaling*, vol. 18, no. 3, pp. 270–287, 2013.
- [53] N. Shahani and A. Sawa, "Protein S-nitrosylation: Role for nitric oxide signaling in neuronal death," *Biochimica et Biophysica Acta*, vol. 1820, no. 6, pp. 736–742, 2012.
- [54] M. A. Corson, N. L. James, S. E. Latta, R. M. Nerem, B. C. Berk, and D. G. Harrison, "Phosphorylation of endothelial nitric oxide synthase in response to fluid shear stress," *Circulation Research*, vol. 79, no. 5, pp. 984–991, 1996.
- [55] B. Fisslthaler, S. Dimmeler, C. Hermann, R. Busse, and I. Fleming, "Phosphorylation and activation of the endothelial nitric oxide synthase by fluid shear stress," *Acta Physiologica Scandinavica*, vol. 168, no. 1, pp. 81–88, 2000.
- [56] S. Dimmeler, I. Fleming, B. Fisslthaler, C. Hermann, R. Busse, and A. M. Zeiher, "Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation," *Nature*, vol. 399, no. 6736, pp. 601–605, 1999.
- [57] D. Fulton, J. P. Gratton, T. J. McCabe et al., "Regulation of endothelium-derived nitric oxide production by the protein kinase Akt," *Nature*, vol. 399, no. 6736, pp. 597–601, 1999.
- [58] T. J. McCabe, D. Fulton, L. J. Roman, and W. C. Sessa, "Enhanced Electron Flux and Reduced Calmodulin Dissociation May Explain "Calcium-independent" eNOS Activation by Phosphorylation*," *The Journal of Biological Chemistry*, vol. 275, no. 9, pp. 6123–6128, 2000.
- [59] K. Komeima, Y. Hayashi, Y. Naito, and Y. Watanabe, "Inhibition of Neuronal Nitric-oxide Synthase by Calcium/Calmodulin-dependent Protein Kinase II α through Ser⁸⁴⁷ Phosphorylation in NG108-15 Neuronal Cells," *The Journal of Biological Chemistry*, vol. 275, no. 36, pp. 28139–28143, 2000.
- [60] Y. Hayashi, M. Nishio, Y. Naito et al., "Regulation of Neuronal Nitric-oxide Synthase by Calmodulin Kinases," *The Journal of Biological Chemistry*, vol. 274, no. 29, pp. 20597–20602, 1999.
- [61] D. I. Pattison, M. J. Davies, and C. L. Hawkins, "Reactions and reactivity of myeloperoxidase-derived oxidants: differential biological effects of hypochlorous and hypothiocyanous acids," *Free Radical Research*, vol. 46, no. 8, pp. 975–995, 2012.
- [62] B. S. Rayner, D. T. Love, and C. L. Hawkins, "Comparative reactivity of myeloperoxidase-derived oxidants with mammalian cells," *Free Radical Biology & Medicine*, vol. 71, pp. 240–255, 2014.
- [63] S. N. Rana, X. Li, I. H. Chaudry, K. I. Bland, and M. A. Choudhry, "Inhibition of IL-18 reduces myeloperoxidase activity and prevents edema in intestine following alcohol and burn injury," *Journal of Leukocyte Biology*, vol. 77, no. 5, pp. 719–728, 2005.
- [64] R. S. McConnico, D. Weinstock, M. E. Poston, and M. C. Roberts, "Myeloperoxidase activity of the large intestine in an equine model of acute colitis," *American Journal of Veterinary Research*, vol. 60, no. 7, pp. 807–813, 1999.
- [65] B. Chami, N. J. J. Martin, J. M. Dennis, and P. K. Witting, "Myeloperoxidase in the inflamed colon: a novel target for treating inflammatory bowel disease," *Archives of Biochemistry and Biophysics*, vol. 645, pp. 61–71, 2018.
- [66] A. Kocael, B. B. Inal, G. Guntas et al., "Evaluation of matrix metalloproteinase, myeloperoxidase, and oxidative damage in mesenteric ischemia-reperfusion injury," *Human & Experimental Toxicology*, vol. 35, no. 8, pp. 851–860, 2016.
- [67] W. M. Nauseef, "Biosynthesis of human myeloperoxidase," *Archives of Biochemistry and Biophysics*, vol. 642, pp. 1–9, 2018.
- [68] M. Hansson, I. Olsson, and W. M. Nauseef, "Biosynthesis, processing, and sorting of human myeloperoxidase," *Archives of Biochemistry and Biophysics*, vol. 445, no. 2, pp. 214–224, 2006.
- [69] U. Gullberg, E. Andersson, D. Garwicz, A. Lindmark, and I. Olsson, "Biosynthesis, processing and sorting of neutrophil proteins: insight into neutrophil granule development," *European Journal of Haematology*, vol. 58, no. 3, pp. 137–153, 1997.
- [70] S. R. Zaki, G. E. Austin, W. C. Chan et al., "Chromosomal localization of the human myeloperoxidase gene by in situ hybridization using oligonucleotide probes," *Genes, Chromosomes & Cancer*, vol. 2, no. 4, pp. 266–270, 1990.
- [71] G. E. Austin, W. G. Zhao, W. Zhang, E. D. Austin, H. W. Findley, and J. J. Murtagh, "Identification and characterization of the human myeloperoxidase promoter," *Leukemia*, vol. 9, no. 5, pp. 848–857, 1995.

- [72] G. E. Austin, W. G. Zhao, A. Adjiri, and J. P. Lu, "Control of myeloperoxidase gene expression in developing myeloid cells," *Leukemia Research*, vol. 20, no. 10, pp. 817–820, 1996.
- [73] K. M. Lin and G. E. Austin, "Functional activity of three distinct myeloperoxidase (MPO) promoters in human myeloid cells," *Leukemia*, vol. 16, no. 6, pp. 1143–1153, 2002.
- [74] M. Lübbert, C. W. Miller, and H. P. Koeffler, "Changes of DNA methylation and chromatin structure in the human myeloperoxidase gene during myeloid differentiation," *Blood*, vol. 78, no. 2, pp. 345–356, 1991.
- [75] K. Hashinaka and M. Yamada, "Undermethylation and DNase I hypersensitivity of myeloperoxidase gene in HL-60 cells before and after differentiation," *Archives of Biochemistry and Biophysics*, vol. 293, no. 1, pp. 40–45, 1992.
- [76] K. Hashinaka, C. Nishio, S. J. Hur, F. Sakiyama, S. Tsunasawa, and M. Yamada, "Multiple species of myeloperoxidase messenger RNAs produced by alternative splicing and differential polyadenylation," *Biochemistry*, vol. 27, no. 16, pp. 5906–5914, 1988.
- [77] J. Suzow and A. D. Friedman, "The murine myeloperoxidase promoter contains several functional elements, one of which binds a cell type-restricted transcription factor, myeloid nuclear factor 1 (MyNF1)," *Molecular and Cellular Biology*, vol. 13, no. 4, pp. 2141–2151, 1993.
- [78] I. Nuchprayoon, S. Meyers, L. M. Scott, J. Suzow, S. Hiebert, and A. D. Friedman, "PEBP2/CBF, the murine homolog of the human myeloid AML1 and PEBP2 beta/CBF beta proto-oncoproteins, regulates the murine myeloperoxidase and neutrophil elastase genes in immature myeloid cells," *Molecular and Cellular Biology*, vol. 14, no. 8, pp. 5558–5568, 1994.
- [79] F. J. Piedrafita, R. B. Molander, G. Vansant, E. A. Orlova, M. Pfahl, and W. F. Reynolds, "An Alu Element in the Myeloperoxidase Promoter Contains a Composite SP1-Thyroid Hormone-Retinoic Acid Response Element," *The Journal of Biological Chemistry*, vol. 271, no. 24, pp. 14412–14420, 1996.
- [80] G. Vansant and W. F. Reynolds, "The consensus sequence of a major Alu subfamily contains a functional retinoic acid response element," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 92, no. 18, pp. 8229–8233, 1995.
- [81] H. N. Kirkman and G. F. Gaetani, "Catalase: a tetrameric enzyme with four tightly bound molecules of NADPH," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 81, no. 14, pp. 4343–4347, 1984.
- [82] M. Connock and W. Pover, "Catalase particles in the epithelial cells of the guinea-pig small intestine," *The Histochemical Journal*, vol. 2, no. 5, pp. 371–380, 1970.
- [83] C. D. Putnam, A. S. Arvai, Y. Bourne, and J. A. Tainer, "Active and inhibited human catalase structures: ligand and NADPH binding and catalytic mechanism¹," *Journal of Molecular Biology*, vol. 296, no. 1, pp. 295–309, 2000.
- [84] C. Glorieux, M. Zamocky, J. M. Sandoval, J. Verrax, and P. B. Calderon, "Regulation of catalase expression in healthy and cancerous cells," *Free Radical Biology & Medicine*, vol. 87, pp. 84–97, 2015.
- [85] R. Rafikov, S. Kumar, S. Aggarwal et al., "Endothelin-1 stimulates catalase activity through the PKC δ -mediated phosphorylation of serine 167," *Free Radical Biology & Medicine*, vol. 67, pp. 255–264, 2014.
- [86] H. Yan and J. J. Harding, "Glycation-induced inactivation and loss of antigenicity of catalase and superoxide dismutase," *The Biochemical Journal*, vol. 328, no. 2, pp. 599–605, 1997.
- [87] H. Furuta, A. Hachimori, Y. Ohta, and A. T. Samejima, "Dissociation of bovine liver catalase into subunits on acetylation," *Journal of Biochemistry*, vol. 76, no. 3, pp. 481–491, 1974.
- [88] M. Y. Kang, H. B. Kim, C. Piao et al., "The critical role of catalase in prooxidant and antioxidant function of p53," *Cell Death and Differentiation*, vol. 20, no. 1, pp. 117–129, 2013.
- [89] D. Watters, P. Kedar, K. Spring et al., "Localization of a Portion of Extranuclear ATM to Peroxisomes," *The Journal of Biological Chemistry*, vol. 274, no. 48, pp. 34277–34282, 1999.
- [90] N. C. Gibbons, J. M. Wood, H. Rokos, and K. U. Schallreuter, "Computer simulation of native epidermal enzyme structures in the presence and absence of hydrogen peroxide (H₂O₂): potential and pitfalls," *The Journal of Investigative Dermatology*, vol. 126, no. 12, pp. 2576–2582, 2006.
- [91] A. M. Vetrano, D. E. Heck, T. M. Mariano, V. Mishin, D. L. Laskin, and J. D. Laskin, "Characterization of the Oxidase Activity in Mammalian Catalase*," *The Journal of Biological Chemistry*, vol. 280, no. 42, pp. 35372–35381, 2005.
- [92] E. Margoliash, A. Novogrodsky, and A. Schejter, "Irreversible reaction of 3-amino-1:2:4-triazole and related inhibitors with the protein of catalase," *The Biochemical Journal*, vol. 74, no. 2, pp. 339–348, 1960.
- [93] L. A. Sigfrid, J. M. Cunningham, N. Beeharry et al., "Cytokines and nitric oxide inhibit the enzyme activity of catalase but not its protein or mRNA expression in insulin-producing cells," *Journal of Molecular Endocrinology*, vol. 31, no. 3, pp. 509–518, 2003.
- [94] A. F. Miller, "Superoxide dismutases: ancient enzymes and new insights," *FEBS Letters*, vol. 586, no. 5, pp. 585–595, 2012.
- [95] C. L. Fattman, L. M. Schaefer, and T. D. Oury, "Extracellular superoxide dismutase in biology and medicine," *Free Radical Biology & Medicine*, vol. 35, no. 3, pp. 236–256, 2003.
- [96] L. Banci, L. Barbieri, I. Bertini et al., "Atomic-resolution monitoring of protein maturation in live human cells by NMR," *Nature Chemical Biology*, vol. 9, no. 5, pp. 297–299, 2013.
- [97] J. W. Slot, H. J. Geuze, B. A. Freeman, and J. D. Crapo, "Intracellular localization of the copper-zinc and manganese superoxide dismutases in rat liver parenchymal cells," *Laboratory Investigation*, vol. 55, no. 3, pp. 363–371, 1986.
- [98] T. Fukai, R. J. Folz, U. Landmesser, and D. G. Harrison, "Extracellular superoxide dismutase and cardiovascular disease," *Cardiovascular Research*, vol. 55, no. 2, pp. 239–249, 2002.
- [99] W. C. Stallings, K. A. Patridge, R. K. Strong, and M. L. Ludwig, "The structure of manganese superoxide dismutase from *Thermus thermophilus* HB8 at 2.4-Å resolution," *The Journal of Biological Chemistry*, vol. 260, no. 30, pp. 16424–16432, 1985.
- [100] G. E. Borgstahl, H. E. Parge, M. J. Hickey, W. F. Beyer Jr., R. A. Hallewell, and J. A. Tainer, "The structure of human mitochondrial manganese superoxide dismutase reveals a novel tetrameric interface of two 4-helix bundles," *Cell*, vol. 71, no. 1, pp. 107–118, 1992.
- [101] M. L. Ludwig, A. L. Metzger, K. A. Patridge, and W. C. Stallings, "Manganese superoxide dismutase from *Thermus thermophilus*: A structural model refined at 1.8 Å

- resolution," *Journal of Molecular Biology*, vol. 219, no. 2, pp. 335–358, 1991.
- [102] G. E. Borgstahl, H. E. Parge, M. J. Hickey et al., "Human mitochondrial manganese superoxide dismutase polymorphic variant Ile58Thr reduces activity by destabilizing the tetrameric interface," *Biochemistry*, vol. 35, no. 14, pp. 4287–4297, 1996.
- [103] I. A. Abreu and D. E. Cabelli, "Superoxide dismutases—a review of the metal-associated mechanistic variations," *Biochimica et Biophysica Acta*, vol. 1804, no. 2, pp. 263–274, 2010.
- [104] C. Bull, E. C. Niederhoffer, T. Yoshida, and J. A. Fee, "Kinetic studies of superoxide dismutases: properties of the manganese-containing protein from *Thermus thermophilus*," *Journal of the American Chemical Society*, vol. 113, no. 11, pp. 4069–4076, 1991.
- [105] I. A. Abreu, J. A. Rodriguez, and D. E. Cabelli, "Theoretical studies of manganese and iron superoxide dismutases: superoxide binding and superoxide oxidation," *The Journal of Physical Chemistry B*, vol. 109, no. 51, pp. 24502–24509, 2005.
- [106] A. S. Hearn, M. E. Stroupe, D. E. Cabelli et al., "Catalytic and structural effects of amino acid substitution at histidine 30 in human manganese superoxide dismutase: insertion of valine C gamma into the substrate access channel," *Biochemistry*, vol. 42, no. 10, pp. 2781–2789, 2003.
- [107] V. J. Lévêque, M. E. Stroupe, J. R. Lepock et al., "Multiple replacements of glutamine 143 in human manganese superoxide dismutase: effects on structure, stability, and catalysis," *Biochemistry*, vol. 39, no. 24, pp. 7131–7137, 2000.
- [108] J. Zheng, J. F. Domsic, D. Cabelli, R. McKenna, and D. N. Silverman, "Structural and kinetic study of differences between human and *Escherichia coli* manganese superoxide dismutases," *Biochemistry*, vol. 46, no. 51, pp. 14830–14837, 2007.
- [109] Y. Furukawa and T. V. O'Halloran, "Posttranslational modifications in Cu,Zn-superoxide dismutase and mutations associated with amyotrophic lateral sclerosis," *Antioxidants & Redox Signaling*, vol. 8, no. 5-6, pp. 847–867, 2006.
- [110] L. Flohé and R. Brigelius-Flohé, "Basics and News on Glutathione Peroxidases, in Selenium," in *Selenium*, pp. 211–222, Springer, Cham, 2016.
- [111] S. C. Tosatto, V. Bosello, F. Fogolari et al., "The catalytic site of glutathione peroxidases," *Antioxidants & Redox Signaling*, vol. 10, no. 9, pp. 1515–1526, 2008.
- [112] S. Toppo, S. Vanin, V. Bosello, and S. C. E. Tosatto, "Evolutionary and structural insights into the multifaceted glutathione peroxidase (Gpx) superfamily," *Antioxidants & Redox Signaling*, vol. 10, no. 9, pp. 1501–1514, 2008.
- [113] J. T. Rotruck, A. L. Pope, H. E. Ganther, A. B. Swanson, D. G. Hafeman, and W. G. Hoekstra, "Selenium: biochemical role as a component of glutathione peroxidase," *Science*, vol. 179, no. 4073, pp. 588–590, 1973.
- [114] M. Mariotti, P. G. Ridge, Y. Zhang et al., "Composition and evolution of the vertebrate and mammalian selenoproteomes," *PLoS One*, vol. 7, no. 3, p. e33066, 2012.
- [115] S. Herbette, P. Roeckel-Drevet, and J. R. Drevet, "Selenium-independent glutathione peroxidases. More than simple antioxidant scavengers," *The FEBS Journal*, vol. 274, no. 9, pp. 2163–2180, 2007.
- [116] T. N. Dear, K. Campbell, and T. H. Rabbitts, "Molecular cloning of putative odorant-binding and odorant-metabolizing proteins," *Biochemistry*, vol. 30, no. 43, pp. 10376–10382, 1991.
- [117] F. Ursini, M. Maiorino, M. Valente, L. Ferri, and C. Gregolin, "Purification from pig liver of a protein which protects liposomes and biomembranes from peroxidative degradation and exhibits glutathione peroxidase activity on phosphatidylcholine hydroperoxides," *Biochimica et Biophysica Acta*, vol. 710, no. 2, pp. 197–211, 1982.
- [118] N. Avissar, D. B. Ornt, Y. Yagil et al., "Human kidney proximal tubules are the main source of plasma glutathione peroxidase," *The American Journal of Physiology*, vol. 266, no. 2, pp. C367–C375, 1994.
- [119] N. B. Ghyselinck and J. P. Dufaure, "A mouse cDNA sequence for epididymal androgen-regulated proteins related to glutathione peroxidase," *Nucleic Acids Research*, vol. 18, no. 23, p. 7144, 1990.
- [120] L. Hall, K. Williams, A. C. Perry, J. Frayne, and J. A. Jury, "The majority of human glutathione peroxidase type 5 (GPX5) transcripts are incorrectly spliced: implications for the role of GPX5 in the male reproductive tract," *The Biochemical Journal*, vol. 333, no. 1, pp. 5–9, 1998.
- [121] A. Utomo, X. Jiang, S. Furuta et al., "Identification of a Novel Putative Non-selenocysteine Containing Phospholipid Hydroperoxide Glutathione Peroxidase (NPGPx) Essential for Alleviating Oxidative Stress Generated from Polyunsaturated Fatty Acids in Breast Cancer Cells*," *The Journal of Biological Chemistry*, vol. 279, no. 42, pp. 43522–43529, 2004.
- [122] J. E. Drew, A. J. Farquharson, J. R. Arthur, P. C. Morrice, and G. G. Duthie, "Novel sites of cytosolic glutathione peroxidase expression in colon," *FEBS Letters*, vol. 579, no. 27, pp. 6135–6139, 2005.
- [123] T. Maseko, K. Howell, F. R. Dunshea, and K. Ng, "Selenium-enriched *Agaricus bisporus* increases expression and activity of glutathione peroxidase-1 and expression of glutathione peroxidase-2 in rat colon," *Food Chemistry*, vol. 146, pp. 327–333, 2014.
- [124] A. Jerome-Morais, M. E. Wright, R. Liu et al., "Inverse association between glutathione peroxidase activity and both selenium-binding protein 1 levels and Gleason score in human prostate tissue," *Prostate*, vol. 72, no. 9, pp. 1006–1012, 2012.
- [125] Y. Higashi, A. Pandey, B. Goodwin, and P. Delafontaine, "Insulin-like growth factor-1 regulates glutathione peroxidase expression and activity in vascular endothelial cells: implications for atheroprotective actions of insulin-like growth factor-1," *Biochimica et Biophysica Acta*, vol. 1832, no. 3, pp. 391–399, 2013.
- [126] A. Holley, J. Pitman, J. Miller, S. Harding, and P. Larsen, "Glutathione peroxidase activity and expression levels are significantly increased in acute coronary syndromes," *Journal of Investigative Medicine*, vol. 65, no. 5, pp. 919–925, 2017.
- [127] F. Felice, D. Lucchesi, R. di Stefano et al., "Oxidative stress in response to high glucose levels in endothelial cells and in endothelial progenitor cells: evidence for differential glutathione peroxidase-1 expression," *Microvascular Research*, vol. 80, no. 3, pp. 332–338, 2010.
- [128] R. M. Johnson, Y. S. Ho, D. Y. Yu, F. A. Kuypers, Y. Ravindranath, and G. W. Goyette, "The effects of disruption of genes for peroxiredoxin-2, glutathione peroxidase-1, and catalase on erythrocyte oxidative metabolism," *Free Radical Biology & Medicine*, vol. 48, no. 4, pp. 519–525, 2010.
- [129] F. F. Chu, J. H. Doroshov, and R. S. Esworthy, "Expression, characterization, and tissue distribution of a new cellular

- selenium-dependent glutathione peroxidase," *GSHPx-GI. J Biol Chem*, vol. 268, no. 4, pp. 2571–2576, 1993.
- [130] R. S. Esworthy, K. M. Swiderek, Y. S. Ho, and F. F. Chu, "Selenium-dependent glutathione peroxidase-GI is a major glutathione peroxidase activity in the mucosal epithelium of rodent intestine¹," *Biochimica et Biophysica Acta*, vol. 1381, no. 2, pp. 213–226, 1998.
- [131] F. F. Chu, H. A. Rohan de Silva, R. S. Esworthy et al., "Polymorphism and Chromosomal Localization of the GI-Form of Human Glutathione Peroxidase (GPX2) on 14q24.1 by *in Situ* Hybridization," *Genomics*, vol. 32, no. 2, pp. 272–276, 1996.
- [132] J. C. Whitin, S. Bhamre, D. M. Tham, and H. J. Cohen, "Extracellular glutathione peroxidase is secreted basolaterally by human renal proximal tubule cells," *American Journal of Physiology. Renal Physiology*, vol. 283, no. 1, pp. F20–F28, 2002.
- [133] R. F. Burk, G. E. Olson, V. P. Winfrey, K. E. Hill, and D. Yin, "Glutathione peroxidase-3 produced by the kidney binds to a population of basement membranes in the gastrointestinal tract and in other tissues," *American Journal of Physiology. Gastrointestinal and Liver Physiology*, vol. 301, no. 1, pp. G32–G38, 2011.
- [134] F. Ursini, S. Heim, M. Kiess et al., "Dual function of the selenoprotein PHGPx during sperm maturation," *Science*, vol. 285, no. 5432, pp. 1393–1396, 1999.
- [135] J. P. Thomas, P. G. Geiger, M. Maiorino, F. Ursini, and A. W. Girotti, "Enzymatic reduction of phospholipid and cholesterol hydroperoxides in artificial bilayers and lipoproteins," *Biochimica et Biophysica Acta*, vol. 1045, no. 3, pp. 252–260, 1990.
- [136] M. Maiorino, V. Bosello-Travain, G. Cozza et al., "Understanding mammalian glutathione peroxidase 7 in the light of its homologs," *Free Radical Biology & Medicine*, vol. 83, pp. 352–360, 2015.
- [137] V. D. Nguyen, M. J. Saaranen, A. R. Karala et al., "Two endoplasmic reticulum PDI peroxidases increase the efficiency of the use of peroxide during disulfide bond formation," *Journal of Molecular Biology*, vol. 406, no. 3, pp. 503–515, 2011.
- [138] T. Ramming and C. Appenzeller-Herzog, "Destroy and exploit: catalyzed removal of hydroperoxides from the endoplasmic reticulum," *International journal of cell biology*, vol. 2013, Article ID 180906, 13 pages, 2013.
- [139] F. F. Chu and R. S. Esworthy, "The expression of an intestinal form of glutathione peroxidase (GSHPx-GI) in rat intestinal epithelium," *Archives of Biochemistry and Biophysics*, vol. 323, no. 2, pp. 288–294, 1995.
- [140] S. Florian, K. Winkler, K. Schmehl et al., "Cellular and subcellular localization of gastrointestinal glutathione peroxidase in normal and malignant human intestinal tissue," *Free Radical Research*, vol. 35, no. 6, pp. 655–663, 2001.
- [141] S. Florian, S. Krehl, M. Loewinger et al., "Loss of GPx2 increases apoptosis, mitosis, and Gpx1 expression in the intestine of mice," *Free Radical Biology & Medicine*, vol. 49, no. 11, pp. 1694–1702, 2010.
- [142] G. E. Olson, J. C. Whitin, K. E. Hill et al., "Extracellular glutathione peroxidase (Gpx3) binds specifically to basement membranes of mouse renal cortex tubule cells," *American Journal of Physiology. Renal Physiology*, vol. 298, no. 5, pp. F1244–F1253, 2010.
- [143] K. Winkler, M. Böcher, L. Flohé, H. Kollmus, and R. Brigelius-Flohé, "mRNA stability and selenocysteine insertion sequence efficiency rank gastrointestinal glutathione peroxidase high in the hierarchy of selenoproteins," *European Journal of Biochemistry*, vol. 259, no. 1-2, pp. 149–157, 1999.
- [144] I. Chambers, J. Frampton, P. Goldfarb, N. Affara, W. McBain, and P. R. Harrison, "The structure of the mouse glutathione peroxidase gene: the selenocysteine in the active site is encoded by the 'termination' codon, TGA," *The EMBO journal*, vol. 5, no. 6, pp. 1221–1227, 1986.
- [145] X. M. Xu, B. A. Carlson, H. Mix et al., "Biosynthesis of selenocysteine on its tRNA in eukaryotes," *PLoS Biology*, vol. 5, no. 1, p. e4, 2007.
- [146] Q. Shen, F. F. Chu, and P. E. Newburger, "Sequences in the 3'-untranslated region of the human cellular glutathione peroxidase gene are necessary and sufficient for selenocysteine incorporation at the UGA codon," *The Journal of Biological Chemistry*, vol. 268, no. 15, pp. 11463–11469, 1993.
- [147] C. Müller, K. Winkler, and R. Brigelius-Flohé, "3'UTRs of glutathione peroxidases differentially affect selenium-dependent mRNA stability and selenocysteine incorporation efficiency," *Biological Chemistry*, vol. 384, no. 1, pp. 11–18, 2003.
- [148] R. Brigelius-Flohé and M. Maiorino, "Glutathione peroxidases," *Biochimica et Biophysica Acta (BBA) - General Subjects*, vol. 1830, no. 5, pp. 3289–3303, 2013.
- [149] M. E. Budiman, J. L. Bubenik, A. C. Miniard et al., "Eukaryotic initiation factor 4a3 is a selenium-regulated RNA-binding protein that selectively inhibits selenocysteine incorporation," *Molecular Cell*, vol. 35, no. 4, pp. 479–489, 2009.
- [150] T. Ishii, K. Itoh, J. Akasaka et al., "Induction of murine intestinal and hepatic peroxiredoxin MSP23 by dietary butylated hydroxyanisole," *Carcinogenesis*, vol. 21, no. 5, pp. 1013–1016, 2000.
- [151] M. Oláhová and E. A. Veal, "A peroxiredoxin, PRDX-2, is required for insulin secretion and insulin/IIS-dependent regulation of stress resistance and longevity," *Aging Cell*, vol. 14, no. 4, pp. 558–568, 2015.
- [152] Z. Wang, R. Sun, G. Wang et al., "SIRT3-mediated deacetylation of PRDX3 alleviates mitochondrial oxidative damage and apoptosis induced by intestinal ischemia/reperfusion injury," *Redox Biology*, vol. 28, p. 101343, 2020.
- [153] A. Nawata, H. Noguchi, Y. Mazaki et al., "Overexpression of peroxiredoxin 4 affects intestinal function in a dietary mouse model of nonalcoholic fatty liver disease," *PLoS One*, vol. 11, no. 4, p. e0152549, 2016.
- [154] Y. Peng, P. H. Yang, S. S. M. Ng, C. T. Lum, H. F. Kung, and M. C. Lin, "Protection of *Xenopus laevis* Embryos Against Alcohol-induced Delayed Gut Maturation and Growth Retardation by Peroxiredoxin 5 and Catalase," *Journal of Molecular Biology*, vol. 340, no. 4, pp. 819–827, 2004.
- [155] A. E. Gordeeva, A. A. Temnov, A. A. Charnagalov, M. G. Sharapov, E. E. Fesenko, and V. I. Novoselov, "Protective effect of peroxiredoxin 6 in ischemia/reperfusion-induced damage of small intestine," *Digestive Diseases and Sciences*, vol. 60, no. 12, pp. 3610–3619, 2015.
- [156] Z. Cao, D. Bhella, and J. G. Lindsay, "Reconstitution of the mitochondrial PrxIII antioxidant defence pathway: general properties and factors affecting PrxIII activity and oligomeric state," *Journal of Molecular Biology*, vol. 372, no. 4, pp. 1022–1033, 2007.
- [157] K. Tsuji, N. G. Copeland, N. A. Jenkins, and M. Obinata, "Mammalian antioxidant protein complements

- alkylhydroperoxide reductase (ahpC) mutation in *Escherichia coli*,” *The Biochemical Journal*, vol. 307, no. 2, pp. 377–381, 1995.
- [158] D. Y. Jin, H. Z. Chae, S. G. Rhee, and K. T. Jeang, “Regulatory Role for a Novel Human Thioredoxin Peroxidase in NF- κ B Activation*,” *The Journal of Biological Chemistry*, vol. 272, no. 49, pp. 30952–30961, 1997.
- [159] S. W. Kang, I. C. Baines, and S. G. Rhee, “Characterization of a Mammalian Peroxiredoxin That Contains One Conserved Cysteine*,” *The Journal of Biological Chemistry*, vol. 273, no. 11, pp. 6303–6311, 1998.
- [160] S. W. Kang, H. Z. Chae, M. S. Seo, K. Kim, I. C. Baines, and S. G. Rhee, “Mammalian Peroxiredoxin Isoforms Can Reduce Hydrogen Peroxide Generated in Response to Growth Factors and Tumor Necrosis Factor- α *,” *The Journal of Biological Chemistry*, vol. 273, no. 11, pp. 6297–6302, 1998.
- [161] S. G. Rhee, H. A. Woo, I. S. Kil, and S. H. Bae, “Peroxiredoxin Functions as a Peroxidase and a Regulator and Sensor of Local Peroxides*,” *The Journal of Biological Chemistry*, vol. 287, no. 7, pp. 4403–4410, 2012.
- [162] B. Hofmann, H. J. Hecht, and L. Flohé, “Peroxiredoxins,” *Biological Chemistry*, vol. 383, no. 3-4, pp. 347–364, 2002.
- [163] S. G. Rhee, S. W. Kang, T. S. Chang, W. Jeong, and K. Kim, “Peroxiredoxin, a novel family of peroxidases,” *IUBMB Life*, vol. 52, no. 1, pp. 35–41, 2001.
- [164] T. S. Chang, W. Jeong, S. Y. Choi, S. Yu, S. W. Kang, and S. G. Rhee, “Regulation of Peroxiredoxin I Activity by Cdc2-mediated Phosphorylation*,” *The Journal of Biological Chemistry*, vol. 277, no. 28, pp. 25370–25376, 2002.
- [165] Z. A. Wood, E. Schröder, J. Robin Harris, and L. B. Poole, “Structure, mechanism and regulation of peroxiredoxins,” *Trends in Biochemical Sciences*, vol. 28, no. 1, pp. 32–40, 2003.
- [166] R. Chauhan and S. C. Mande, “Characterization of the *Mycobacterium tuberculosis* H37Rv alkyl hydroperoxidase AhpC points to the importance of ionic interactions in oligomerization and activity,” *The Biochemical Journal*, vol. 354, pp. 209–215, 2001.
- [167] K. Kitano, Y. Niimura, Y. Nishiyama, and K. Miki, “Stimulation of peroxidase activity by decamerization related to ionic strength: AhpC protein from *Amphibacillus xylanus*,” *Journal of Biochemistry*, vol. 126, no. 2, pp. 313–319, 1999.
- [168] E. Nogoceke, D. U. Gommel, M. Kiess, H. M. Kalisz, and L. Flohé, “A unique cascade of oxidoreductases catalyses trypanothione-mediated peroxide metabolism in *Crithidia fasciculata*,” *Biological Chemistry*, vol. 378, no. 8, pp. 827–836, 1997.
- [169] K. H. Koo, S. Lee, S. Y. Jeong et al., “Regulation of thioredoxin peroxidase activity by C-terminal truncation,” *Archives of Biochemistry and Biophysics*, vol. 397, no. 2, pp. 312–318, 2002.
- [170] E. Lakari, P. Pykkäs, P. Pietarinen-Runtti, P. Pääkkö, Y. Soini, and V. L. Kinnula, “Expression and regulation of hemoxygenase 1 in healthy human lung and interstitial lung disorders,” *Human Pathology*, vol. 32, no. 11, pp. 1257–1263, 2001.
- [171] A. Zampetaki, T. Minamino, S. A. Mitsialis, and S. Kourembanas, “Effect of heme oxygenase-1 overexpression in two models of lung inflammation,” *Experimental Biology and Medicine*, vol. 228, no. 5, pp. 442–446, 2003.
- [172] I. Bauer, H. Rensing, A. Florax et al., “Expression pattern and regulation of heme oxygenase-1/heat shock protein 32 in human liver cells,” *Shock*, vol. 20, no. 2, pp. 116–122, 2003.
- [173] S. Takahashi, T. Takahashi, S. Mizobuchi et al., “CYP2E1 overexpression up-regulates both non-specific delta-aminolevulinic synthase and heme oxygenase-1 in the human hepatoma cell line HLE/2E1,” *International Journal of Molecular Medicine*, vol. 11, no. 1, pp. 57–62, 2003.
- [174] K. Inoue, T. Takahashi, K. Uehara et al., “Protective role of heme oxygenase 1 in the intestinal tissue injury in hemorrhagic shock in rats,” *Shock*, vol. 29, no. 2, pp. 252–261, 2008.
- [175] D. W. Rosenberg and A. Kappas, “Characterization of heme oxygenase in the small intestinal epithelium,” *Archives of Biochemistry and Biophysics*, vol. 274, no. 2, pp. 471–480, 1989.
- [176] N. Seiwert, S. Wecklein, P. Demuth et al., “Heme oxygenase 1 protects human colonocytes against ROS formation, oxidative DNA damage and cytotoxicity induced by heme iron, but not inorganic iron,” *Cell Death & Disease*, vol. 11, no. 9, p. 787, 2020.
- [177] R. Eyssen-Hernandez, A. Ladoux, and C. Frelin, “Differential regulation of cardiac heme oxygenase-1 and vascular endothelial growth factor mRNA expressions by hemin, heavy metals, heat shock and anoxia,” *FEBS Letters*, vol. 382, no. 3, pp. 229–233, 1996.
- [178] P. J. Lee, J. Alam, G. W. Wiegand, and A. M. Choi, “Overexpression of heme oxygenase-1 in human pulmonary epithelial cells results in cell growth arrest and increased resistance to hyperoxia,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 93, no. 19, pp. 10393–10398, 1996.
- [179] M. S. Carraway, A. J. Ghio, J. D. Carter, and C. A. Piantadosi, “Expression of heme oxygenase-1 in the lung in chronic hypoxia,” *American Journal of Physiology. Lung Cellular and Molecular Physiology*, vol. 278, no. 4, pp. L806–L812, 2000.
- [180] D. Lautier, P. Luscher, and R. M. Tyrrell, “Endogenous glutathione levels modulate both constitutive and UVA radiation/hydrogen peroxide inducible expression of the human heme oxygenase gene,” *Carcinogenesis*, vol. 13, no. 2, pp. 227–232, 1992.
- [181] J. F. Ewing and M. D. Maines, “Rapid induction of heme oxygenase 1 mRNA and protein by hyperthermia in rat brain: heme oxygenase 2 is not a heat shock protein,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 88, no. 12, pp. 5364–5368, 1991.
- [182] M. S. Carraway, A. J. Ghio, J. L. Taylor, and C. A. Piantadosi, “Induction of ferritin and heme oxygenase-1 by endotoxin in the lung,” *The American Journal of Physiology*, vol. 275, no. 3, pp. L583–L592, 1998.
- [183] Y. Sun, M. O. Rotenberg, and M. D. Maines, “Developmental expression of heme oxygenase isozymes in rat brain. Two HO-2 mRNAs are detected,” *The Journal of Biological Chemistry*, vol. 265, no. 14, pp. 8212–8217, 1990.
- [184] R. M. Müller, H. Taguchi, and S. Shibahara, “Nucleotide sequence and organization of the rat heme oxygenase gene,” *The Journal of Biological Chemistry*, vol. 262, no. 14, pp. 6795–6802, 1987.
- [185] T. Yoshida, P. Biro, T. Cohen, R. M. Müller, and S. Shibahara, “Human heme oxygenase cDNA and induction of its mRNA by hemin,” *European Journal of Biochemistry*, vol. 171, no. 3, pp. 457–461, 1988.
- [186] D. J. Schuller, A. Wilks, P. R. Ortiz de Montellano, and T. L. Poulos, “Crystal structure of human heme oxygenase-1,” *Nature Structural Biology*, vol. 6, no. 9, pp. 860–867, 1999.

- [187] J. Sun, A. Wilks, P. R. Ortiz de Montellano, and T. M. Loehr, "Resonance Raman and EPR spectroscopic studies on heme-heme oxygenase complexes," *Biochemistry*, vol. 32, no. 51, pp. 14151–14157, 1993.
- [188] S. Takahashi, J. Wang, D. L. Rousseau et al., "Heme-heme oxygenase complex. Structure of the catalytic site and its implication for oxygen activation," *The Journal of Biological Chemistry*, vol. 269, no. 2, pp. 1010–1014, 1994.
- [189] M. D. Maines, "The heme oxygenase system: a regulator of second messenger gases," *Annual Review of Pharmacology and Toxicology*, vol. 37, no. 1, pp. 517–554, 1997.
- [190] A. M. Choi and J. Alam, "Heme oxygenase-1: function, regulation, and implication of a novel stress-inducible protein in oxidant-induced lung injury," *American Journal of Respiratory Cell and Molecular Biology*, vol. 15, no. 1, pp. 9–19, 1996.
- [191] L. Zhang, Z. Zhang, B. Liu et al., "The protective effect of heme oxygenase-1 against intestinal barrier dysfunction in cholestatic liver injury is associated with NF- κ B inhibition," *Molecular Medicine*, vol. 23, no. 1, pp. 215–224, 2017.
- [192] J. Dan Dunn, L. A. J. Alvarez, X. Zhang, and T. Soldati, "Reactive oxygen species and mitochondria: a nexus of cellular homeostasis," *Redox Biology*, vol. 6, pp. 472–485, 2015.
- [193] J. P. Collman, N. K. Devaraj, R. A. Decréau et al., "A cytochrome C oxidase model catalyzes oxygen to water reduction under rate-limiting electron flux," *Science*, vol. 315, no. 5818, pp. 1565–1568, 2007.
- [194] M. H. Barros, L. E. Netto, and A. J. Kowaltowski, "H₂O₂ generation in *Saccharomyces cerevisiae* respiratory pet mutants: effect of cytochrome c," *Free Radical Biology & Medicine*, vol. 35, no. 2, pp. 179–188, 2003.
- [195] V. P. Skulachev, "Cytochrome c in the apoptotic and antioxidant cascades," *FEBS Letters*, vol. 423, no. 3, pp. 275–280, 1998.
- [196] C. T. Taylor and S. Moncada, "Nitric oxide, cytochrome C oxidase, and the cellular response to hypoxia," *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 30, no. 4, pp. 643–647, 2010.
- [197] K. Bedard and K. H. Krause, "The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology," *Physiological Reviews*, vol. 87, no. 1, pp. 245–313, 2007.
- [198] H. Sies, "Oxidative stress: a concept in redox biology and medicine," *Redox Biology*, vol. 4, pp. 180–183, 2015.
- [199] V. I. Lushchak, "Free radicals, reactive oxygen species, oxidative stress and its classification," *Chemico-Biological Interactions*, vol. 224, pp. 164–175, 2014.
- [200] H. Sies, C. Berndt, and D. P. Jones, "Oxidative stress," *Annual Review of Biochemistry*, vol. 86, pp. 715–748, 2017.
- [201] H. Sies and D. P. Jones, "Reactive oxygen species (ROS) as pleiotropic physiological signalling agents," *Nature Reviews. Molecular Cell Biology*, vol. 21, no. 7, pp. 363–383, 2020.
- [202] T. Y. Aw, "Biliary glutathione promotes the mucosal metabolism of luminal peroxidized lipids by rat small intestine in vivo," *The Journal of Clinical Investigation*, vol. 94, no. 3, pp. 1218–1225, 1994.
- [203] P. S. Samiec, L. J. Dahm, and D. P. Jones, "Glutathione S-transferase in mucus of rat small intestine," *Toxicological Sciences*, vol. 54, no. 1, pp. 52–59, 2000.
- [204] M. L. Circu and T. Y. Aw, "Redox biology of the intestine," *Free Radical Research*, vol. 45, no. 11–12, pp. 1245–1266, 2011.
- [205] M. L. Circu and T. Y. Aw, "Intestinal redox biology and oxidative stress," *Seminars in Cell & Developmental Biology*, vol. 23, no. 7, pp. 729–737, 2012.
- [206] S. P. Wolff and J. Nourooz-Zadeh, "Hypothesis: UK consumption of dietary lipid hydroperoxides—a possible contributory factor to atherosclerosis," *Atherosclerosis*, vol. 119, no. 2, pp. 261–263, 1996.
- [207] T. Y. Aw, "Intestinal glutathione: determinant of mucosal peroxide transport, metabolism, and oxidative susceptibility," *Toxicology and Applied Pharmacology*, vol. 204, no. 3, pp. 320–328, 2005.
- [208] S. Tsunada, R. Iwakiri, T. Noda et al., "Chronic exposure to subtoxic levels of peroxidized lipids suppresses mucosal cell turnover in rat small intestine and reversal by glutathione," *Digestive Diseases and Sciences*, vol. 48, no. 1, pp. 210–222, 2003.
- [209] Y. M. Go and D. P. Jones, "Redox compartmentalization in eukaryotic cells," *Biochimica et Biophysica Acta*, vol. 1780, no. 11, pp. 1273–1290, 2008.
- [210] D. P. Jones and Y. M. Go, "Redox compartmentalization and cellular stress," *Diabetes, Obesity and Metabolism*, vol. 12, pp. 116–125, 2010.
- [211] L. J. Dahm and D. P. Jones, "Rat jejunum controls luminal thiol-disulfide redox," *The Journal of Nutrition*, vol. 130, no. 11, pp. 2739–2745, 2000.
- [212] S. E. Moriarty-Craige and D. P. Jones, "Extracellular thiols and thiol/disulfide redox in metabolism," *Annual Review of Nutrition*, vol. 24, pp. 481–509, 2004.
- [213] Y. Park, T. R. Ziegler, N. Gletsu-Miller et al., "Postprandial cysteine/cystine redox potential in human plasma varies with meal content of sulfur amino acids," *The Journal of Nutrition*, vol. 140, no. 4, pp. 760–765, 2010.
- [214] D. A. Dickinson and H. J. Forman, "Glutathione in defense and signaling: lessons from a small thiol," *Annals of the New York Academy of Sciences*, vol. 973, pp. 488–504, 2002.
- [215] M. H. Stipanuk, "Sulfur amino acid metabolism: pathways for production and removal of homocysteine and cysteine," *Annual Review of Nutrition*, vol. 24, pp. 539–577, 2004.
- [216] L. H. Lash and D. P. Jones, "Characteristics of cysteine uptake in intestinal basolateral membrane vesicles," *The American Journal of Physiology*, vol. 247, pp. G394–G401, 1984.
- [217] R. A. Blanco, T. R. Ziegler, B. A. Carlson et al., "Diurnal variation in glutathione and cysteine redox states in human plasma," *The American Journal of Clinical Nutrition*, vol. 86, no. 4, pp. 1016–1023, 2007.
- [218] H. F. Gilbert, "Molecular and cellular aspects of thiol-disulfide exchange," *Advances in Enzymology and Related Areas of Molecular Biology*, vol. 63, pp. 69–172, 1990.
- [219] L. J. Dahm and D. P. Jones, "Secretion of cysteine and glutathione from mucosa to lumen in rat small intestine," *The American Journal of Physiology*, vol. 267, pp. G292–G300, 1994.
- [220] E. Scharrer, E. Senn, and S. Wolfram, "Stimulation of mucosal uptake of selenium from selenite by some thiols at various sites of rat intestine," *Biological Trace Element Research*, vol. 33, pp. 109–120, 1992.
- [221] D. Snary, A. Allen, and R. H. Pain, "Structural studies on gastric mucoproteins: lowering of molecular weight after reduction with 2-mercaptoethanol," *Biochemical and Biophysical Research Communications*, vol. 40, no. 4, pp. 844–851, 1970.
- [222] M. W. Neil, "The absorption of cystine and cysteine from rat small intestine," *The Biochemical Journal*, vol. 71, no. 1, pp. 118–124, 1959.

- [223] Y. O. Mannery, T. R. Ziegler, L. Hao, Y. Shyntum, and D. P. Jones, "Characterization of apical and basal thiol-disulfide redox regulation in human colonic epithelial cells," *American Journal of Physiology. Gastrointestinal and Liver Physiology*, vol. 299, no. 2, pp. G523–G530, 2010.
- [224] S. J. Forrester, D. S. Kikuchi, M. S. Hernandez, Q. Xu, and K. K. Griendling, "Reactive oxygen species in metabolic and inflammatory signaling," *Circulation Research*, vol. 122, no. 6, pp. 877–902, 2018.
- [225] H. Sies, "Hydrogen peroxide as a central redox signaling molecule in physiological oxidative stress: oxidative eustress," *Redox Biology*, vol. 11, pp. 613–619, 2017.
- [226] C. C. Winterbourn, "The biological chemistry of hydrogen peroxide," *Methods in Enzymology*, vol. 528, pp. 3–25, 2013.
- [227] C. R. Reczek and N. S. Chandel, "ROS-dependent signal transduction," *Current Opinion in Cell Biology*, vol. 33, pp. 8–13, 2015.
- [228] M. C. Sobotta, W. Liou, S. Stöcker et al., "Peroxiredoxin-2 and STAT3 form a redox relay for H₂O₂ signaling," *Nature Chemical Biology*, vol. 11, no. 1, pp. 64–70, 2015.
- [229] P. A. Karplus, "A primer on peroxiredoxin biochemistry," *Free Radical Biology & Medicine*, vol. 80, pp. 183–190, 2015.
- [230] W. Jeong, S. H. Bae, M. B. Toledano, and S. G. Rhee, "Role of sulfiredoxin as a regulator of peroxiredoxin function and regulation of its expression," *Free Radical Biology & Medicine*, vol. 53, no. 3, pp. 447–456, 2012.
- [231] B. Chance, H. Sies, and A. Boveris, "Hydroperoxide metabolism in mammalian organs," *Physiological Reviews*, vol. 59, no. 3, pp. 527–605, 1979.
- [232] H. Sies, "Role of metabolic H₂O₂ generation: redox signaling and oxidative stress," *The Journal of Biological Chemistry*, vol. 289, no. 13, pp. 8735–8741, 2014.
- [233] N. Oshino, B. Chance, H. Sies, and T. Bücher, "The role of H₂O₂ generation in perfused rat liver and the reaction of catalase compound I and hydrogen donors," *Archives of Biochemistry and Biophysics*, vol. 154, no. 1, pp. 117–131, 1973.
- [234] P. Surai, "Antioxidant-prooxidant balance in the intestine: applications in chick placement and pig weaning," *Journal of Veterinary Science & Medicine*, vol. 3, 2015.
- [235] S. Pérez, R. Taléns-Visconti, S. Rius-Pérez, I. Finamor, and J. Sastre, "Redox signaling in the gastrointestinal tract," *Free Radical Biology & Medicine*, vol. 104, pp. 75–103, 2017.
- [236] D. B. Longley, D. P. Harkin, and P. G. Johnston, "5-fluorouracil: mechanisms of action and clinical strategies," *Nature Reviews Cancer*, vol. 3, no. 5, pp. 330–338, 2003.
- [237] R. V. Lalla and D. E. Peterson, "Treatment of mucositis, including new medications," *Cancer Journal*, vol. 12, no. 5, pp. 348–354, 2006.
- [238] M. Yasuda, S. Kato, N. Yamanaka et al., "5-HT₃ receptor antagonists ameliorate 5-fluorouracil-induced intestinal mucositis by suppression of apoptosis in murine intestinal crypt cells," *British Journal of Pharmacology*, vol. 168, no. 6, pp. 1388–1400, 2013.
- [239] K. Rtibi, S. Selmi, D. Grami, M. Amri, H. Sebai, and L. Marzouki, "Contribution of oxidative stress in acute intestinal mucositis induced by 5 fluorouracil (5-FU) and its pro-drug capecitabine in rats," *Toxicology Mechanisms and Methods*, vol. 28, no. 4, pp. 262–267, 2018.
- [240] D. V. S. Costa, A. C. Bon-Frauches, A. M. H. P. Silva et al., "5-Fluorouracil induces enteric neuron death and glial activation during intestinal mucositis via a S100B-RAGE-NFκB-dependent pathway," *Scientific Reports*, vol. 9, no. 1, p. 665, 2019.
- [241] A. K. Al-Asmari, A. Q. Khan, S. A. Al-Asmari, A. Al-Rawi, and S. Al-Omani, "Alleviation of 5-fluorouracil-induced intestinal mucositis in rats by vitamin E via targeting oxidative stress and inflammatory markers," *Journal of complementary and integrative medicine*, vol. 13, no. 4, pp. 377–385, 2016.
- [242] C. Wang, S. Yang, L. Gao, L. Wang, and L. Cao, "Carboxymethyl pachyman (CMP) reduces intestinal mucositis and regulates the intestinal microflora in 5-fluorouracil-treated CT26 tumour-bearing mice," *Food & Function*, vol. 9, no. 5, pp. 2695–2704, 2018.
- [243] E. X. dos Santos Filho, A. C. G. da Silva, R. I. de Ávila et al., "Chemopreventive effects of FITOPROT against 5-fluorouracil-induced toxicity in HaCaT cells," *Life Sciences*, vol. 193, pp. 300–308, 2018.
- [244] S. Qiu, P. Li, H. Zhao, and X. Li, "Maresin 1 alleviates dextran sulfate sodium-induced ulcerative colitis by regulating NRF2 and TLR4/NF-κB signaling pathway," *International Immunopharmacology*, vol. 78, p. 106018, 2020.
- [245] B. Liu, X. Piao, W. Niu et al., "Kuijiejuan decoction improved intestinal barrier injury of ulcerative colitis by affecting TLR4-dependent PI3K/AKT/NF-κB oxidative and inflammatory signaling and gut microbiota," *Frontiers in Pharmacology*, vol. 11, p. 1036, 2020.
- [246] X.-X. Yan, H. L. Li, Y. T. Zhang et al., "A new recombinant MS-superoxide dismutase alleviates 5-fluorouracil-induced intestinal mucositis in mice," *Acta Pharmacologica Sinica*, vol. 41, no. 3, pp. 348–357, 2020.
- [247] J. Ali, A. U. Khan, F. A. Shah et al., "Mucoprotective effects of Saikosaponin-A in 5-fluorouracil-induced intestinal mucositis in mice model," *Life Sciences*, vol. 239, p. 116888, 2019.
- [248] H. Takano, Y. Momota, K. Kani et al., "γ-tocotrienol prevents 5-FU-induced reactive oxygen species production in human oral keratinocytes through the stabilization of 5-FU-induced activation of Nrf2," *International Journal of Oncology*, vol. 46, no. 4, pp. 1453–1460, 2015.
- [249] K. Itoh, N. Wakabayashi, Y. Katoh et al., "Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain," *Genes & Development*, vol. 13, no. 1, pp. 76–86, 1999.
- [250] G. Pepe, S. F. Rapa, E. Salviati et al., "Bioactive polyphenols from pomegranate juice reduce 5-fluorouracil-induced intestinal mucositis in intestinal epithelial cells," *Antioxidants*, vol. 9, no. 8, p. 699, 2020.
- [251] D. Trachootham, J. Alexandre, and P. Huang, "Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?," *Nature Reviews Drug Discovery*, vol. 8, no. 7, pp. 579–591, 2009.
- [252] T. W. Kensler, N. Wakabayashi, and S. Biswal, "Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway," *Annual Review of Pharmacology and Toxicology*, vol. 47, pp. 89–116, 2007.
- [253] M. S. Yates, M. Tauchi, F. Katsuoka et al., "Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes," *Molecular Cancer Therapeutics*, vol. 6, no. 1, pp. 154–162, 2007.
- [254] A. K. MacLeod, M. McMahon, S. M. Plummer et al., "Characterization of the cancer chemopreventive NRF2-dependent gene battery in human keratinocytes: demonstration that

- the KEAP1-NRF2 pathway, and not the BACH1-NRF2 pathway, controls cytoprotection against electrophiles as well as redox-cycling compounds,” *Carcinogenesis*, vol. 30, no. 9, pp. 1571–1580, 2009.
- [255] K. F. Hui, B. H. W. Lam, D. N. Ho, S. W. Tsao, and A. K. S. Chiang, “Bortezomib and SAHA synergistically induce ROS-driven caspase-dependent apoptosis of nasopharyngeal carcinoma and block replication of Epstein-Barr virus,” *Molecular Cancer Therapeutics*, vol. 12, no. 5, pp. 747–758, 2013.
- [256] X.-X. Chen, K. H. Lam, Q. X. Chen et al., “*Ficus virens* proanthocyanidins induced apoptosis in breast cancer cells concomitantly ameliorated 5-fluorouracil induced intestinal mucositis in rats,” *Food and Chemical Toxicology*, vol. 110, pp. 49–61, 2017.
- [257] M. G. Mahmoud, M. S. Selim, S. S. Mohamed, A. I. Hassan, and S. A. Abdal-Aziz, “Study of the chemical structure of exopolysaccharide produced from streptomyces and its effect as an attenuate for antineoplastic drug 5-fluorouracil that induced gastrointestinal toxicity in rats,” *Animal Biotechnology*, vol. 31, no. 5, pp. 397–412, 2020.
- [258] C. C. Cunha Bastos, P. H. M. de Ávila, E. X. dos Santos Filho et al., “Use of *Bidens pilosa* L. (Asteraceae) and *Curcuma longa* L. (Zingiberaceae) to treat intestinal mucositis in mice: Toxicopharmacological evaluations,” *Toxicology Reports*, vol. 3, pp. 279–287, 2016.
- [259] Z. Guo, Q. Chen, B. Liu, D. Tian, S. Zhang, and M. Li, “LRIG1 enhances chemosensitivity by modulating BCL-2 expression and receptor tyrosine kinase signaling in glioma cells,” *Yonsei Medical Journal*, vol. 55, no. 5, pp. 1196–1205, 2014.
- [260] T. H. Liu, W. Q. Tu, W. C. Tao, Q. E. Liang, Y. Xiao, and L. G. Chen, “Verification of resveratrol inhibits intestinal aging by downregulating ATF4/Chop/Bcl-2/Bax signaling pathway: based on network pharmacology and animal experiment,” *Frontiers in Pharmacology*, vol. 11, p. 1064, 2020.
- [261] J. A. Taminiau, D. G. Gall, and J. R. Hamilton, “Response of the rat small-intestine epithelium to methotrexate,” *Gut*, vol. 21, no. 6, pp. 486–492, 1980.
- [262] C. R. Pinkerton, C. H. Cameron, J. M. Sloan, J. F. Glasgow, and N. J. Gwevava, “Jejunal crypt cell abnormalities associated with methotrexate treatment in children with acute lymphoblastic leukaemia,” *Journal of Clinical Pathology*, vol. 35, no. 11, pp. 1272–1277, 1982.
- [263] Y. Gao, Q. Sun, X. Yang et al., “Orally administered salean ameliorates methotrexate-induced intestinal mucositis in mice,” *Cancer Chemotherapy and Pharmacology*, vol. 84, no. 1, pp. 105–116, 2019.
- [264] L. Kaynar, A. Cetin, S. K. Hacioglu et al., “Efficacy of royal jelly on methotrexate-induced systemic oxidative stress and damage to small intestine in rats,” *African Journal of Traditional, Complementary, and Alternative Medicines*, vol. 9, no. 3, pp. 412–417, 2012.
- [265] X. Shi, J. F. Lin, H. H. Chang, G. A. Lee, and C. F. Hung, “Lutein protects against methotrexate-induced and reactive oxygen species-mediated apoptotic cell injury of IEC-6 cells,” *PLoS One*, vol. 8, no. 9, 2013.
- [266] K. Natarajan and P. Abraham, “Methotrexate administration induces differential and selective protein tyrosine nitration and cysteine nitrosylation in the subcellular organelles of the small intestinal mucosa of rats,” *Chemico-Biological Interactions*, vol. 251, pp. 45–59, 2016.
- [267] V. K. Kolli, K. Natarajan, B. Isaac, D. Selvakumar, and P. Abraham, “Mitochondrial dysfunction and respiratory chain defects in a rodent model of methotrexate-induced enteritis,” *Human & Experimental Toxicology*, vol. 33, no. 10, pp. 1051–1065, 2014.
- [268] A. Ozcicek, N. Cetin, F. Keskin Cimen et al., “The impact of resveratrol on oxidative stress induced by methotrexate in rat ileum tissue: evaluation of biochemical and histopathological features and analysis of gene expression,” *Medical Principles and Practice*, vol. 25, no. 2, pp. 181–186, 2016.
- [269] F. Ozcicek, A. V. Kara, E. M. Akbas et al., “Effects of anakinra on the small intestine mucositis induced by methotrexate in rats,” *Experimental Animals*, vol. 69, no. 2, pp. 144–152, 2020.
- [270] C. J. Shi, X. S. Wen, H. F. Gao et al., “Steamed root of *Rehmannia glutinosa* Libosch (Plantaginaceae) alleviates methotrexate-induced intestinal mucositis in rats,” *Journal of Ethnopharmacology*, vol. 183, pp. 143–150, 2016.
- [271] K. D. Pfeffer, T. P. Huecksteadt, and J. R. Hoidal, “Xanthine dehydrogenase and xanthine oxidase activity and gene expression in renal epithelial cells. Cytokine and steroid regulation,” *The Journal of Immunology*, vol. 153, no. 4, pp. 1789–1797, 1994.
- [272] Y. Yang, S. Li, Y. Qu et al., “Nitrate partially inhibits lipopolysaccharide-induced inflammation by maintaining mitochondrial function,” *The Journal of International Medical Research*, vol. 48, no. 2, p. 030006052090260, 2020.
- [273] V. K. Kolli, I. Kanakasabapathy, M. Faith et al., “A preclinical study on the protective effect of melatonin against methotrexate-induced small intestinal damage: effect mediated by attenuation of nitrosative stress, protein tyrosine nitration, and PARP activation,” *Cancer Chemotherapy and Pharmacology*, vol. 71, no. 5, pp. 1209–1218, 2013.
- [274] A. P. Kumar, F. J. Piedrafita, and W. F. Reynolds, “Peroxisome proliferator-activated receptor gamma ligands regulate myeloperoxidase expression in macrophages by an estrogen-dependent mechanism involving the -463GA promoter polymorphism,” *The Journal of Biological Chemistry*, vol. 279, no. 9, pp. 8300–8315, 2004.
- [275] P. Lefebvre, G. Chinetti, J. C. Fruchart, and B. Staels, “Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis,” *The Journal of Clinical Investigation*, vol. 116, no. 3, pp. 571–580, 2006.
- [276] S. N. Khan, R. Yennamalli, N. Subbarao, and A. U. Khan, “Mitoxantrone induced impediment of histone acetylation and structural flexibility of the protein,” *Cell Biochemistry and Biophysics*, vol. 60, no. 3, pp. 209–218, 2011.
- [277] T. B. Lee, Y. S. Moon, and C. H. Choi, “Histone H4 deacetylation down-regulates catalase gene expression in doxorubicin-resistant AML subline,” *Cell Biology and Toxicology*, vol. 28, no. 1, pp. 11–18, 2012.
- [278] D. R. Freyer, L. Chen, M. D. Krailo et al., “Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial,” *The Lancet Oncology*, vol. 18, no. 1, pp. 63–74, 2017.
- [279] R. Rezaee, A. A. Momtazi, A. Monemi, and A. Sahebkar, “Curcumin: a potentially powerful tool to reverse cisplatin-induced toxicity,” *Pharmacological Research*, vol. 117, pp. 218–227, 2017.
- [280] G. J. Dugbartey, L. J. Peppone, and I. A. de Graaf, “An integrative view of cisplatin-induced renal and cardiac toxicities:

- molecular mechanisms, current treatment challenges and potential protective measures,” *Toxicology*, vol. 371, pp. 58–66, 2016.
- [281] A. Rebillard, N. Rioux-Leclercq, C. Muller et al., “Acid sphingomyelinase deficiency protects from cisplatin-induced gastrointestinal damage,” *Oncogene*, vol. 27, no. 51, pp. 6590–6595, 2008.
- [282] F. Shahid, Z. Farooqui, and F. Khan, “Cisplatin-induced gastrointestinal toxicity: an update on possible mechanisms and on available gastroprotective strategies,” *European Journal of Pharmacology*, vol. 827, pp. 49–57, 2018.
- [283] Y. Tazuke, K. Maeda, M. Wasa, N. Satoko, and M. Fukuzawa, “Protective mechanism of glutamine on the expression of proliferating cell nuclear antigen after cisplatin-induced intestinal mucosal injury,” *Pediatric Surgery International*, vol. 27, no. 2, pp. 151–158, 2011.
- [284] A. Alimonti, A. Gelibter, I. Pavese et al., “New approaches to prevent intestinal toxicity of irinotecan-based regimens,” *Cancer Treatment Reviews*, vol. 30, no. 6, pp. 555–562, 2004.
- [285] Y. Wu, D. Wang, X. Yang, C. Fu, L. Zou, and J. Zhang, “Traditional Chinese medicine Gegen Qinlian decoction ameliorates irinotecan chemotherapy-induced gut toxicity in mice,” *Bio-medicine & Pharmacotherapy*, vol. 109, pp. 2252–2261, 2019.
- [286] T. Suzuki and M. Yamamoto, “Molecular basis of the Keap1-Nrf2 system,” *Free Radical Biology & Medicine*, vol. 88, pp. 93–100, 2015.
- [287] G. Gloire, S. Legrand-Poels, and J. Piette, “NF-kappaB activation by reactive oxygen species: fifteen years later,” *Biochemical Pharmacology*, vol. 72, no. 11, pp. 1493–1505, 2006.
- [288] A. U. Dignass, D. C. Baumgart, and A. Sturm, “Review article: the aetiopathogenesis of inflammatory bowel disease—immunology and repair mechanisms,” *Alimentary Pharmacology & Therapeutics*, vol. 20, Supplement 4, pp. 9–17, 2004.
- [289] C. Ma, X. Yang, Q. Lv et al., “Soluble uric acid induces inflammation via TLR4/NLRP3 pathway in intestinal epithelial cells,” *Iranian Journal of Basic Medical Sciences*, vol. 23, no. 6, pp. 744–750, 2020.
- [290] D. Jour'dheuil, F. L. Jour'dheuil, P. S. Kutchukian, R. A. Musah, D. A. Wink, and M. B. Grisham, “Reaction of Superoxide and Nitric Oxide with Peroxynitrite,” *The Journal of Biological Chemistry*, vol. 276, no. 31, pp. 28799–28805, 2001.
- [291] C. Richter, “Reactive oxygen and nitrogen species regulate mitochondrial Ca²⁺ homeostasis and respiration,” *Bioscience Reports*, vol. 17, no. 1, pp. 53–66, 1997.
- [292] P. Kubes and D. M. McCafferty, “Nitric oxide and intestinal inflammation,” *The American Journal of Medicine*, vol. 109, no. 2, pp. 150–158, 2000.
- [293] T. G. Wang, Y. Gotoh, M. H. Jennings, C. A. Rhoads, and T. Y. Aw, “Lipid hydroperoxide-induced apoptosis in human colonic CaCo-2 cells is associated with an early loss of cellular redox balance,” *The FASEB Journal*, vol. 14, no. 11, pp. 1567–1576, 2000.
- [294] Y. Zhuang, H. Wu, X. Wang, J. He, S. He, and Y. Yin, “Resveratrol attenuates oxidative stress-induced intestinal barrier injury through PI3K/Akt-mediated Nrf2 signaling pathway,” *Oxidative Medicine and Cellular Longevity*, vol. 2019, Article ID 7591840, 14 pages, 2019.
- [295] L.-N. Liu, Q. B. Mei, L. Liu et al., “Protective effects of Rheum tanguticum polysaccharide against hydrogen peroxide-induced intestinal epithelial cell injury,” *World Journal of Gastroenterology: WJG*, vol. 11, no. 10, pp. 1503–1507, 2005.
- [296] V. Ranna, K. K. F. Cheng, D. A. Castillo et al., “Development of the MASCC/ISOO clinical practice guidelines for mucositis: an overview of the methods,” *Support Care Cancer*, vol. 27, no. 10, pp. 3933–3948, 2019.
- [297] R. D. N. Arifa, M. F. M. Madeira, T. P. de Paula et al., “Inflammasome Activation Is Reactive Oxygen Species Dependent and Mediates Irinotecan-Induced Mucositis through IL-1 β and IL-18 in Mice,” *American Journal of Pathology*, vol. 184, no. 7, pp. 2023–2034, 2014.
- [298] Y. Miyazono, F. Gao, and T. Horie, “Oxidative stress contributes to methotrexate-induced small intestinal toxicity in rats,” *Scandinavian Journal of Gastroenterology*, vol. 39, no. 11, pp. 1119–1127, 2004.
- [299] O. G. R. Azevedo, R. A. C. Oliveira, B. C. Oliveira et al., “Apolipoprotein E COG 133 mimetic peptide improves 5-fluorouracil-induced intestinal mucositis,” *BMC Gastroenterology*, vol. 12, no. 1, 2012.
- [300] T. Xia, J. Zhang, L. Han et al., “Protective effect of magnolol on oxaliplatin-induced intestinal injury in mice,” *Phytotherapy Research*, vol. 33, no. 4, pp. 1161–1172, 2019.
- [301] L. S. Fideles, J. A. L. de Miranda, C. S. Martins et al., “Role of rutin in 5-fluorouracil-induced intestinal mucositis: prevention of histological damage and reduction of inflammation and oxidative stress,” *Molecules*, vol. 25, no. 12, p. 2786, 2020.
- [302] M. M. Antunes, P. C. L. Leocádio, L. G. Teixeira et al., “Pretreatment with L-citrulline positively affects the mucosal architecture and permeability of the small intestine in a murine mucositis model,” *Journal of Parenteral and Enteral Nutrition*, vol. 40, no. 2, pp. 279–286, 2016.
- [303] J. A. Leal de Miranda, J. E. F. Barreto, D. S. Martins et al., “Protective effect of cashew gum (*Anacardium occidentale* L.) on 5-fluorouracil-induced intestinal mucositis,” *Pharmaceuticals*, vol. 12, no. 2, p. 51, 2019.
- [304] F. M. Peradeles Galdino, M. E. R. Andrade, P. A. V. de Barros et al., “Pretreatment and treatment with fructooligosaccharides attenuate intestinal mucositis induced by 5-FU in mice,” *Journal of Functional Foods*, vol. 49, pp. 485–492, 2018.
- [305] P. C. L. Leocadio, M. M. Antunes, L. G. Teixeira et al., “L-Arginine pretreatment reduces intestinal mucositis as induced by 5-FU in mice,” *Nutrition And Cancer-an International Journal*, vol. 67, no. 3, pp. 486–493, 2015.
- [306] A. K. Al-Asmari, A. M. Al-Zahrani, A. Q. Khan, H. M. Al-Shahrani, and M. Ali Al Amri, “Taurine ameliorates 5-fluorouracil-induced intestinal mucositis, hepatorenal and reproductive organ damage in Wistar rats: a biochemical and histological study,” *Human & Experimental Toxicology*, vol. 35, no. 1, pp. 10–20, 2016.
- [307] J. A. L. de Miranda, C. D. S. Martins, L. D. S. Fideles et al., “Trolox prevents 5-fluorouracil induced morphological changes in the intestinal mucosa: role of cyclooxygenase-2 pathway,” *Pharmaceuticals*, vol. 13, no. 1, p. 10, 2020.
- [308] B. A. A. Porto, C. F. Monteiro, É. L. S. Souza et al., “Treatment with selenium-enriched *Saccharomyces cerevisiae* UFMG A-905 partially ameliorates mucositis induced by 5-fluorouracil in mice,” *Cancer Chemotherapy and Pharmacology*, vol. 84, no. 1, pp. 117–126, 2019.
- [309] S. H. Kim, H. J. Chun, H. S. Choi et al., “Ursodeoxycholic acid attenuates 5-fluorouracil-induced mucositis in a rat model,” *Oncology Letters*, vol. 16, no. 2, pp. 2585–2590, 2018.
- [310] V. K. Kolli, P. Abraham, B. Isaac, and N. Kasthuri, “Preclinical efficacy of melatonin to reduce methotrexate-induced

- oxidative stress and small intestinal damage in rats," *Digestive Diseases and Sciences*, vol. 58, no. 4, pp. 959–969, 2013.
- [311] R. D. N. Arifa, T. P. Paula, M. F. M. Madeira et al., "The reduction of oxidative stress by nanocomposite Fullerol decreases mucositis severity and reverts leukopenia induced by Irinotecan," *Pharmacological Research*, vol. 107, pp. 102–110, 2016.
- [312] T. Boeing, P. Souza, S. Specia et al., "Luteolin prevents irinotecan-induced intestinal mucositis in mice through antioxidant and anti-inflammatory properties," *British Journal of Pharmacology*, vol. 177, no. 10, pp. 2393–2408, 2020.
- [313] T. Tong, Y. H. Niu, Y. Yue, S. C. Wu, and H. Ding, "Beneficial effects of anthocyanins from red cabbage (*Brassica oleracea* L. var. *capitata* L.) administration to prevent irinotecan-induced mucositis," *Journal of Functional Foods*, vol. 32, pp. 9–17, 2017.
- [314] A. Atiq, B. Shal, M. Naveed et al., "Diadzein ameliorates 5-fluorouracil-induced intestinal mucositis by suppressing oxidative stress and inflammatory mediators in rodents," *Euro-pean Journal of Pharmacology*, vol. 843, pp. 292–306, 2019.
- [315] A. K. Al-Asmari, A. Q. Khan, A. M. Al-Qasim, and Y. Al-Yousef, "Ascorbic acid attenuates antineoplastic drug 5-fluorouracil induced gastrointestinal toxicity in rats by modulating the expression of inflammatory mediators," *Toxicology Reports*, vol. 2, pp. 908–916, 2015.
- [316] T. A. F. M. Magalhaes, M. O. D. Souza, S. V. Gomes et al., "Açaí (*Euterpe oleracea* Martius) promotes jejunal tissue regeneration by enhancing antioxidant response in 5-fluorouracil-induced mucositis," *Nutrition And Cancer-an International Journal*, vol. 73, no. 3, pp. 523–533, 2021.
- [317] H. Zheng, J. Gao, S. Man, J. Zhang, Z. Jin, and W. Gao, "The protective effects of *Aquilariae Lignum Resinatum* extract on 5-Fuorouracil-induced intestinal mucositis in mice," *Phyto-medicine*, vol. 54, pp. 308–317, 2019.
- [318] V. Kesik, B. Uysal, B. Kurt, E. Kismet, and V. Koseoglu, "Ozone ameliorates methotrexate-induced intestinal injury in rats," *Cancer Biology & Therapy*, vol. 8, no. 17, pp. 1623–1628, 2009.
- [319] L. Deng, H. Zeng, X. Hu et al., "Se@Albumin nanoparticles ameliorate intestinal mucositis caused by cisplatin via gut microbiota-targeted regulation," *Nanoscale*, vol. 13, no. 25, pp. 11250–11261, 2021.
- [320] C.-H. Wu, J. L. Ko, J. M. Liao et al., "D-methionine alleviates cisplatin-induced mucositis by restoring the gut microbiota structure and improving intestinal inflammation," *Medical Oncology*, vol. 11, p. 175883591882102, 2019.
- [321] R. Levit, G. Savoy de Giori, A. de Moreno de LeBlanc, and J. G. LeBlanc, "Protective effect of the riboflavin-overproducing strain *Lactobacillus plantarum* CRL2130 on intestinal mucositis in mice," *Nutrition*, vol. 54, pp. 165–172, 2018.
- [322] T. Maeda, Y. Miyazono, K. Ito, K. Hamada, S. Sekine, and T. Horie, "Oxidative stress and enhanced paracellular permeability in the small intestine of methotrexate-treated rats," *Cancer Chemotherapy and Pharmacology*, vol. 65, no. 6, pp. 1117–1123, 2010.
- [323] F. Gao and T. Horie, "A synthetic analog of prostaglandin E₁ prevents the production of reactive oxygen species in the intestinal mucosa of methotrexate-treated rats," *Life Sciences*, vol. 71, no. 9, pp. 1091–1099, 2002.
- [324] S. Kalthoff, S. Paulusch, A. Rupp, S. Holdenrieder, G. Hartmann, and C. P. Strassburg, "The coffee ingredients caffeic acid and caffeic acid phenylethyl ester protect against irinotecan-induced leukopenia and oxidative stress response," *British Journal of Pharmacology*, vol. 177, no. 18, pp. 4193–4208, 2020.
- [325] R. W. Bastos, S. H. S. P. Pedroso, A. T. Vieira et al., "Saccharomyces cerevisiae UFMG A-905 treatment reduces intestinal damage in a murine model of irinotecan-induced mucositis," *Beneficial Microbes*, vol. 7, no. 4, pp. 549–557, 2016.
- [326] M. Marsova, M. Odorskaya, M. Novichkova et al., "The *Lactobacillus brevis* 47 f strain protects the murine intestine from enteropathy induced by 5-fluorouracil," *Microorganisms*, vol. 8, no. 6, p. 876, 2020.
- [327] V. L. Bodiga, S. Bodiga, S. Surampudi et al., "Effect of vitamin supplementation on cisplatin-induced intestinal epithelial cell apoptosis in Wistar/NIN rats," *Nutrition*, vol. 28, no. 5, pp. 572–580, 2012.
- [328] P. F. Justino, L. F. M. Melo, A. F. Nogueira et al., "Treatment with *Saccharomyces boulardii* reduces the inflammation and dysfunction of the gastrointestinal tract in 5-fluorouracil-induced intestinal mucositis in mice," *The British Journal of Nutrition*, vol. 111, no. 9, pp. 1611–1621, 2014.